
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59B59D925FC5C33AB59D002FC48B37.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmjgroup">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Neurology, Neurosurgery, and Psychiatry">
<meta name="citation_title" content="Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis">
<meta name="citation_author" content="Antonia Carroll">
<meta name="citation_author_institution" content="Brain and Mind Centre, Faculty of Medicine and Health, Translational Research Collective, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia">
<meta name="citation_author" content="P James Dyck">
<meta name="citation_author_institution" content="Neurology, Mayo Clinic, Rochester, Minnesota, USA">
<meta name="citation_author" content="Mamede de Carvalho">
<meta name="citation_author_institution" content="Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal">
<meta name="citation_author_institution" content="Department of Neurosciences and Mental Health, Hospital de Santa Maria, Lisboa, Portugal">
<meta name="citation_author" content="Marina Kennerson">
<meta name="citation_author_institution" content="Northcott Neuroscience Laboratory, ANZAC Research Institute, Molecular Medicine Laboratory Concord Repatriation General Hospital, and Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia">
<meta name="citation_author" content="Mary M Reilly">
<meta name="citation_author_institution" content="MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK">
<meta name="citation_author" content="Matthew C Kiernan">
<meta name="citation_author_institution" content="Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia">
<meta name="citation_author_institution" content="Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia">
<meta name="citation_author" content="Steve Vucic">
<meta name="citation_author_institution" content="Brain and Nerve Research Center, Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia">
<meta name="citation_publication_date" content="2022 Mar 7">
<meta name="citation_volume" content="93">
<meta name="citation_issue" content="6">
<meta name="citation_firstpage" content="668">
<meta name="citation_doi" content="10.1136/jnnp-2021-327909">
<meta name="citation_pmid" content="35256455">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/pdf/jnnp-2021-327909.pdf">
<meta name="description" content="Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant inherited systemic disease predominantly affecting the peripheral and autonomic nervous system, heart, kidney and the eyes. ATTRv is caused by mutations of the ...">
<meta name="og:title" content="Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant inherited systemic disease predominantly affecting the peripheral and autonomic nervous system, heart, kidney and the eyes. ATTRv is caused by mutations of the ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="9148983">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1136/jnnp-2021-327909"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/jnnp-2021-327909.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9148983%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/9148983/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/9148983/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmjgroup.png" alt="BMJ Open Access logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMJ Open Access" title="Link to BMJ Open Access" shape="default" href="https://doi.org/10.1136/jnnp-2021-327909" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Neurol Neurosurg Psychiatry</button></div>. 2022 Mar 7;93(6):668–678. doi: <a href="https://doi.org/10.1136/jnnp-2021-327909" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1136/jnnp-2021-327909</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22J%20Neurol%20Neurosurg%20Psychiatry%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Neurol%20Neurosurg%20Psychiatry%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Neurol%20Neurosurg%20Psychiatry%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Neurol%20Neurosurg%20Psychiatry%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carroll%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Antonia Carroll</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Antonia Carroll</span></h3>
<div class="p">
<sup>1</sup>
Brain and Mind Centre, Faculty of Medicine and Health, Translational Research Collective, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carroll%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonia Carroll</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dyck%20PJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">P James Dyck</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">P James Dyck</span></h3>
<div class="p">
<sup>2</sup>
Neurology, Mayo Clinic, Rochester, Minnesota, USA
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dyck%20PJ%22%5BAuthor%5D" class="usa-link"><span class="name western">P James Dyck</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Carvalho%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Mamede de Carvalho</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Mamede de Carvalho</span></h3>
<div class="p">
<sup>3</sup>
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
</div>
<div class="p">
<sup>4</sup>
Department of Neurosciences and Mental Health, Hospital de Santa Maria, Lisboa, Portugal
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Carvalho%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mamede de Carvalho</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kennerson%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Marina Kennerson</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Marina Kennerson</span></h3>
<div class="p">
<sup>5</sup>
Northcott Neuroscience Laboratory, ANZAC Research Institute, Molecular Medicine Laboratory Concord Repatriation General Hospital, and Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kennerson%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marina Kennerson</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reilly%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Mary M Reilly</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Mary M Reilly</span></h3>
<div class="p">
<sup>6</sup>
MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reilly%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Mary M Reilly</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kiernan%20MC%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Matthew C Kiernan</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Matthew C Kiernan</span></h3>
<div class="p">
<sup>7</sup>
Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia
</div>
<div class="p">
<sup>8</sup>
Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kiernan%20MC%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthew C Kiernan</span></a>
</div>
</div>
<sup>7,</sup><sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vucic%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Steve Vucic</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Steve Vucic</span></h3>
<div class="p">
<sup>9</sup>
Brain and Nerve Research Center, Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vucic%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Steve Vucic</span></a>
</div>
</div>
<sup>9,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>
Brain and Mind Centre, Faculty of Medicine and Health, Translational Research Collective, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
</div>
<div id="aff2">
<sup>2</sup>
Neurology, Mayo Clinic, Rochester, Minnesota, USA
</div>
<div id="aff3">
<sup>3</sup>
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
</div>
<div id="aff4">
<sup>4</sup>
Department of Neurosciences and Mental Health, Hospital de Santa Maria, Lisboa, Portugal
</div>
<div id="aff5">
<sup>5</sup>
Northcott Neuroscience Laboratory, ANZAC Research Institute, Molecular Medicine Laboratory Concord Repatriation General Hospital, and Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia
</div>
<div id="aff6">
<sup>6</sup>
MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
</div>
<div id="aff7">
<sup>7</sup>
Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia
</div>
<div id="aff8">
<sup>8</sup>
Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
</div>
<div id="aff9">
<sup>9</sup>
Brain and Nerve Research Center, Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia
</div>
<div class="author-notes p">
<div class="fn" id="corresp1">
<sup>✉</sup><p class="display-inline">
Correspondence to Professor Steve Vucic, Brain and Nerve Research Center, Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia; <span>steve.vucic@sydney.edu.au</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p">
<section id="article-meta1" class="series-info"><h3 class="pmc_sec_title">Series information</h3>
<p>Review</p></section><section id="historyarticle-meta1" class="history"><p>Received 2021 Nov 25; Accepted 2022 Feb 12; Issue date 2022 Jun.</p></section>
</div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</div>
<p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC9148983  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35256455/" class="usa-link">35256455</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant inherited systemic disease predominantly affecting the peripheral and autonomic nervous system, heart, kidney and the eyes. ATTRv is caused by mutations of the transthyretin (TTR) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. Typically, the neuropathy associated with ATTRv is characterised by a rapidly progressive and disabling sensorimotor axonal neuropathy with early small-fibre involvement. Carpal tunnel syndrome and cardiac dysfunction frequently coexist as part of the ATTRv phenotype. Although awareness of ATTRv polyneuropathy among neurologists has increased, the rate of misdiagnosis remains high, resulting in significant diagnostic delays and accrued disability. A timely and definitive diagnosis is important, given the emergence of effective therapies which have revolutionised the management of transthyretin amyloidosis. TTR protein stabilisers diflunisal and tafamidis can delay the progression of the disease, if treated early in the course. Additionally, TTR gene silencing medications, patisiran and inotersen, have resulted in up to 80% reduction in TTR production, leading to stabilisation or slight improvement of peripheral neuropathy and cardiac dysfunction, as well as improvement in quality of life and functional outcomes. The considerable therapeutic advances have raised additional challenges, including optimisation of diagnostic techniques and management approaches in ATTRv neuropathy. This review highlights the key advances in the diagnostic techniques, current and emerging management strategies, and biomarker development for disease progression in ATTRv.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> amyloid, neuropathy</p></section></section><section id="s1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Amyloidoses refer to a heterogeneous group of diseases that are pathologically characterised by aggregation of amyloid-fibril proteins deposited extracellularly, resulting in a toxic gain of function.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> In accordance with the official amyloid fibril protein nomenclature list published by the International Society of Amyloidosis, 36 amyloid fibril proteins are known to cause amyloidosis, with diseases classified according to the nature of the amyloid precursor protein.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2</sup></a> Transthyretin (TTR) is a human 56 kDa non-glycosylated amyloidogenic protein. Hereditary transthyretin amyloidosis (ATTRv) is caused by the deposition of variant TTR protein. The main ATTRv phenotypes include polyneuropathy (hereditary transthyretin amyloidosis–polyneuropathy (ATTRv-PN)), hereditary transthyretin amyloidosis–cardiomyopathy (ATTRv-CM), and renal and ocular involvement. Hereditary transthyretin leptomeningeal amyloidosis (ATTRv-LA) is a rare neurological phenotype. ATTRv has been regarded as a rare endemic disorder; however, advances in diagnostic techniques have indicated that ATTRv is more frequent than previously recognised.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> Wild-type transthyretin amyloidosis (ATTRwt) manifests later and is increasingly recognised as the cause of amyloid cardiomyopathy, although it can also rarely cause peripheral neuropathy.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a>
</p>
<p>Advances in understanding of ATTRv pathogenesis has led to development of novel and therapeutic strategies. Aside from liver transplantation, alternative therapeutic options have including TTR tetramer stabilisers, genomic approaches using antisense oligonucleotide and small interfering RNA (siRNA) technologies, as well as novel TTR protein stabilisers and fibril removers. The following review examines the structure and function of TTR, potential pathophysiological mechanisms in ATTRv and the clinical phenotypes associated with ATTRv. Lastly, utility of therapeutic approaches targeting specific pathophysiological mechanisms in ATTRv will be appraised.</p></section><section id="s2"><h2 class="pmc_sec_title">Structure and function of TTR</h2>
<p>TTR is 55 kDa transport protein that is predominantly synthesised by the liver and secreted into the bloodstream. The main physiological function of TTR is to transport retinol-binding protein–vitamin A complex (holoRBP) and thyroxine (T4). TTR has a tetrameric structure composed of four identical beta-sheet rich subunits with two T4 and four holoRBP-binding sites.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> Studies of TTR knockout (TTR-KO) mice have reported sensorimotor dysfunction and impairment of nerve recovery in response to crush injuries.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> Expression of human TTR in TTR-KO mice rescued the phenotype, reinforcing the importance of TTR in nerve repair.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> A neuroprotective role for TTR in the central nervous system (CNS) has also been reported.<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6</sup></a> TTR is synthesised by the choroid plexus, retinal pigment epithelium and pancreas,<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7</sup></a> where it may contribute to a variety of physiological functions including transport of thyroid hormones.</p></section><section id="s3"><h2 class="pmc_sec_title">Genetics of ATTRv</h2>
<p>ATTRv encompasses a range of phenotypes (<a href="#F1" class="usa-link">figure 1</a>), with autosomal dominant pattern of inheritance. To date, 140 different TTR mutations have been reported, with the Val30Met (p.Val50Met) variant being the most frequent.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> The Val30Met mutation is responsible for high prevalence of ATTRv in endemic areas, including Portugal (incidence 0.87/100 000, prevalence 22.9/100 000),<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9</sup></a> Sweden and Japan.<a href="#R10" class="usa-link" aria-describedby="R10"><sup>10</sup></a> The carrier frequency in the Swedish population is high (~1.5%), with evidence of anticipation (~11.7 years).<a href="#R11" class="usa-link" aria-describedby="R11"><sup>11</sup></a> The risk of anticipation was higher in males and with maternal transmission. In non-endemic regions, the carrier frequency of the Val30Met variant is lower.<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7</sup></a> Carrier frequency markedly varies between racial backgrounds, as underscored by the frequent occurrence of the ATTRv Val122Ile (p.Val142Ile) mutation in Afro-American, West African and Hispanic populations. Distinct founder mutations have been reported in other regions, including the Thr60Ala (p.Thr80Ala) TTR variant in northwest Ireland, and THE Ala97Ser (p.Ala117Ser) variant in China and Taiwan.<a href="#R12" class="usa-link" aria-describedby="R12"><sup>12 13</sup></a>
</p>
<figure class="fig xbox font-sm" id="F1"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9148983_jnnp-2021-327909f01.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e94a/9148983/2bf739795f64/jnnp-2021-327909f01.jpg" loading="lazy" height="360" width="628" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>(A) Clinical features and genotype–phenotype correlations. (A) ATTRv a multisystem disease with a variety of clinical features. The most frequent phenotypes include ATTR polyneuropathy (ATTRv-PN), ATTR cardiomyopathy (ATTRv-CM) and ATTR leptomeningeal amyloidosis (ATTRv-LA). (B) To date, 140 mutations in the ATTR gene (TTR) have been reported that lead to ATTRv. The Val30Met is the most frequent mutation, reported globally and in endemic regions. While mutations may give proclivity to specific phenotypes, a poor correlation between phenotype and genotype has been reported. For example, ATTRv Val30Met may be associated with early-onset and late-onset ATTRv-PN, with a paucity of cardiomyopathy in the former. ATTRwt is predominantly associated with ATTR-CM, with relative absence of neuropathy, although carpal tunnel is a common feature. (B) Modified with permission from Castaño and colleagues.<a href="#R111" class="usa-link" aria-describedby="R111"><sup>111</sup></a> ATTR, transthyretin amyloidosis; ATTR-PN, transthyretin amyloidosis–polyneuropathy; ATTRv, hereditary transthyretin amyloidosis; ATTRv-CM, hereditary transthyretin amyloidosis–cardiomyopathy; ATTRv-LA, hereditary transthyretin leptomeningeal amyloidosis; ATTRv-PN, hereditary transthyretin amyloidosis–polyneuropathy; ATTRwt, wild-type transthyretin amyloidosis; TTR, transthyretin.</p></figcaption></figure><p>Although different TTR mutations may result in phenotypical overlap, mutations causing predominantly neuropathic, cardiomyopathic or mixed phenotypes have been reported (<a href="#F1" class="usa-link">figure 1</a>). Early-onset Val30Met mutations present with peripheral neuropathy, while Thr60Ala variants often manifest as mixed neuropathic and cardiomyopathic phenotypes. In contrast, the Val122Ile variant presents with late-onset disease with predominant cardiac dysfunction.<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7</sup></a> Phenotype heterogeneity has been reported for the same mutations, both across different pedigrees and within familial groups.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> Variability in age of disease onset has been reported, with the best predictor being onset age within the family pedigree. Although ATTRv exhibits an autosomal dominant pattern of inheritance, incomplete penetrance has been described, with different mutations and populations exhibiting varied penetrance rates. While penetrance can be difficult to ascertain for late-onset variants, early-onset phenotypes (Val30Met) have a penetrance of 80% at 50 years and 91% at 70 years in Portuguese, compared with 15% at 50 years in Swedish patients.<a href="#R11" class="usa-link" aria-describedby="R11"><sup>11 15</sup></a> The interaction between carrier frequency, age of onset and penetrance determines population prevalence of ATTRv. While the Val30Met carrier frequency in Portugal is low, the high penetrance and early age of onset result in a high population prevalence.<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9</sup></a>
</p></section><section id="s4"><h2 class="pmc_sec_title">Clinical spectrum of ATTRv phenotype</h2>
<p>ATTRv amyloidosis is a multisystem disease as summarised in <a href="#F1" class="usa-link">figure 1A</a>. Understanding the clinical spectrum of ATTRv will raise suspicion and thereby enable early diagnosis of ATTRv, allowing the institution of effective therapies.</p>
<section id="s4-1"><h3 class="pmc_sec_title">Hereditary transthyretin amyloidosis–polyneuropathy</h3>
<p>ATTRv-PN is the the most common of the amyloid phenotypes and most frequently associated with the Val30Met mutation. <em>Early-onset ATTRv-PN phenotype</em> is common in Portugal and Japan, characterised by onset at &lt;50 years, high penetrance and progressive axonal length‐dependent sensorimotor polyneuropathy.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1 16</sup></a> Small-fibre neuropathy is also frequently reported, characterised by loss of nociception and thermal sensation, burning feet and paresthesias in distal lower extremities.<a href="#R17" class="usa-link" aria-describedby="R17"><sup>17 18</sup></a> Autonomic neuropathy (AN) occurs in ~75% of patients with ATTRv, characterised by orthostatic hypotension (lightheadedness, exercise intolerance and non-specific fatigue), gastrointestinal (gastroparesis, recurrent vomiting, diarrhoea or alternating diarrhoea–constipation and faecal incontinence) and genitourinary (urinary retention, nocturia, incomplete emptying and frequency, and erectile dysfunction) symptoms.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> Autonomic symptoms may be disabling, with high morbidity from arrhythmias and sudden death. Malnutrition and weight loss may ensue, which are adverse prognostic factors. Amyloid deposition in the bowel wall may contribute to gastrointestinal symptoms. Cardiac conduction defects appear frequently, requiring pacemaker implantation, along with myocardial thickening.<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a>
<em>Late-onset ATTRv-PN phenotype</em> begins at &gt;50 years of age and occurs in endemic and non-endemic regions. Clinically, it is characterised by progressive axonal sensorimotor neuropathy affecting all sensory modalities, variable penetrance, lack of family history and milder AN symptoms.<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21–23</sup></a> Neuropathic pain is more frequent than in early-onset ATTRv,<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a> particularly with the Thr60Ala variant.<a href="#R24" class="usa-link" aria-describedby="R24"><sup>24</sup></a> Upper limb-onset axonal neuropathy has also been reported,<a href="#R25" class="usa-link" aria-describedby="R25"><sup>25</sup></a> as have gait ataxia with large-fibre sensory loss, paucity of muscle weakness and generalised areflexia.<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26</sup></a> ATTRv-PN may be misdiagnosed as chronic inflammatory polyradiculoneuropathy, with slowing of motor conduction velocities in the demyelinating range, elevated cerebrospinal fluid (CSF) protein, and paucity of autonomic and systemic involvement.<a href="#R27" class="usa-link" aria-describedby="R27"><sup>27</sup></a> A pure motor syndrome with absence of AN has also been observed in non-Val30Met variants.<a href="#R28" class="usa-link" aria-describedby="R28"><sup>28</sup></a> Amyloid cardiomyopathy and gastrointestinal dysfunction are frequently observed in late-onset ATTRv.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16 21</sup></a>
</p>
<p>Bilateral carpal tunnel syndrome (CTS) frequently occurs in early-onset and late-onset ATTRv-PN and ATTRwt, commonly preceding other organ involvement by years (Rukavina type).<a href="#R22" class="usa-link" aria-describedby="R22"><sup>22</sup></a> Other neuromuscular manifestations include myopathy, exhibiting a limb or axial pattern of muscle weakness, mildly elevated creatine kinase levels, absence of dysphagia and presence of systemic features.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18</sup></a> Spinal canal stenosis is also a feature of transthyretin amyloidosis (ATTR) due to amyloid deposition in the ligamentum flavum, resulting in neurogenic claudication.<a href="#R29" class="usa-link" aria-describedby="R29"><sup>29</sup></a>
</p></section><section id="s4-2"><h3 class="pmc_sec_title">Hereditary transthyretin amyloidosis–cardiomyopathy</h3>
<p>ATTRv-CM is evident in ~50% of patients,<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> and while frequently associated with Val122Ile (~3% to 4% of African-Americans) and Ile111Met (p.Ile131Met) TTR variants, other mutations are more common in Caucasian, Hispanic and Asian populations.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1 16</sup></a> ATTRv-CM is more common in late-onset (Val30Met) ATTRv, manifesting as restrictive cardiac failure, otherwise known as heart failure with preserved ejection fraction (HFpEF), conduction blocks, ventricular arrhythmias or sudden cardiac death.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> ATTRv-CM is indistinguishable by clinical findings or investigation characteristics from ATTRwt–cardiomyopathy. Low-voltage ECG or pseudo-infarct patterns in right praecordial leads are consistent with ATTR-CM. Myocardial thickening, along with subendocardial late gadolinium enhancement, is a characteristic cardiac MRI features<a href="#R30" class="usa-link" aria-describedby="R30"><sup>30</sup></a> Echocardiography demonstrates thickened septal and ventricular walls, impaired diastolic relaxation and reduced global logitudinal strain with an apical sparing pattern.<a href="#R31" class="usa-link" aria-describedby="R31"><sup>31</sup></a> Additionally, 99mTc-pyrophosphate (PYP), 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) or 99mTc-hydroxymethylene diphosphonate (HMDP) scintigraphy is considered the most sensitive for detecting amyloid deposition in ATTR-CM. Myocardial sympathetic denervation, measured by 123-iodine metaiodobenzylguanidine imaging, is an independent predictor of mortality and represents the importance of autonomic changes in ATTR-CM.<a href="#R32" class="usa-link" aria-describedby="R32"><sup>32</sup></a> ATTRv-CM is associated with increased mortality and is the major cause of death in non-endemic regions.<a href="#R33" class="usa-link" aria-describedby="R33"><sup>33</sup></a>
</p></section><section id="s4-3"><h3 class="pmc_sec_title">Leptomeningeal amyloidosis</h3>
<p>ATTRv-LA is a rare manifestation of ATTRv, most frequently associated with non-Val30Met mutations (Leu12Pro, Ala25Thr, Gly53Glu, Tyr114Cys, Asp18Gly or Tyr69His). Pathologically, ATTRv-LA is characterised by cerebral amyloid angiopathy and leptomeningeal amyloidosis.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14 22</sup></a> Amyloid deposits may be evident in the media and adventitia of medium-sized and small-sized cortical arteries, arterioles and veins, as well as veins in the subarachnoid space and leptomeninges. In the CNS, the choroid plexus is the main source of amyloid. Ischaemic strokes and intracerebral haemorrhage, along with subarachnoid haemorrhage and hydrocephalus, are common complications. Symptoms include headaches, hearing or visual loss, cerebral haemorrhages, dementia, ataxia, spasticity, transient focal neurological episodes (amyloid spells) and seizures.<a href="#R34" class="usa-link" aria-describedby="R34"><sup>34</sup></a> Neuropathy is an inconsistent feature of ATTRv-LA.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Separately, ATTRv-LA may be evident in patients with the Val30Met mutation, typically 11 years after liver transplantation, due to ongoing variant TTR production by the choroid plexus.<a href="#R35" class="usa-link" aria-describedby="R35"><sup>35</sup></a> Age-related cognitive dysfunction was reported in older patients with ATTRv (&gt;50 years) with Val30Met, implying the pathogenic importance of centrally produced TTR variant protein.<a href="#R36" class="usa-link" aria-describedby="R36"><sup>36</sup></a> Cranial nerves can be affected, mimicking amyotrophic lateral sclerosis.<a href="#R37" class="usa-link" aria-describedby="R37"><sup>37</sup></a>
</p></section><section id="s4-4"><h3 class="pmc_sec_title">Other organ involvement in ATTRv</h3>
<p>Renal disease, manifesting as proteinuria, nephrotic syndrome and progressive renal failure, occurs in one-third of Portuguese patients (Val30Met), most commonly evident in the late-onset phenotype.<a href="#R38" class="usa-link" aria-describedby="R38"><sup>38 39</sup></a> Microalbuminuria can be the first abnormality, and 10% develop end-stage renal disease secondary to vascular and glomerular amyloid depositions. Ocular involvement, manifesting as dry eyes and keratoconjunctivitis, vitreous opacity due to amyloid deposition, cataracts, secondary open-angle glaucoma and retinal amyloid angiopathy may be evident in up to 25% of patients with ATTRv typically evident with Val30Met mutations.<a href="#R40" class="usa-link" aria-describedby="R40"><sup>40</sup></a> Gastrointestinal symptoms result from both AN and direct deposition of amyloid in the bowel wall, leading to small intestinal bacteria overgrowth (blind-loop phenomenon)<a href="#R41" class="usa-link" aria-describedby="R41"><sup>41</sup></a>
</p></section></section><section id="s5"><h2 class="pmc_sec_title">Wild-type transthyretin amyloidosis</h2>
<p>ATTRwt, previously known as senile systemic amyloidosis, is a common disease of ageing, with autopsy studies disclosing that 10%–25% of over 80-year-olds had wild-type amyloid deposition in the myocardium, and 44% in the gastrointestinal tract and subcutaneous tissue.<a href="#R42" class="usa-link" aria-describedby="R42"><sup>42</sup></a> A significant burden of amyloid deposition is required to cause symptomatic disease, and hence, histopathological deposition does not necessarily equate to clinical significance. ATTRwt presents between the sixth-eighth decades of life, manifesting as HFpEF, atrial fibrillation and ventricular arrhythmias, occasionally requiring implantation of a cardioverter defibrillator.<a href="#R43" class="usa-link" aria-describedby="R43"><sup>43</sup></a> CTS is a common presenting feature,<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21</sup></a> as is spinal canal stenosis, while other systemic manifestations are less frequent.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19 21</sup></a>
</p>
<section id="s5-1"><h3 class="pmc_sec_title">Diagnostic and prognostic biomarkers for ATTR</h3>
<p>The diagnosis of amyloidosis typically relies on pathological identification of amyloid deposits. Congo red staining with apple green birefringence under polarised light represents the pathognomonic appearance of amyloid (<a href="#F2" class="usa-link">figure 2A–C</a>). While biopsy of a target organ has the highest yield, less invasive approaches, including abdominal fat aspiration or salivary gland biopsy, exhibit sensitivities between 50%–80% and specificity of 90%.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> In clinical practice, diagnostic yields are lower, and if clinical suspicion is high, biopsy of involved tissue should be performed.</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9148983_jnnp-2021-327909f02.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e94a/9148983/4cbe0c3df4c4/jnnp-2021-327909f02.jpg" loading="lazy" height="350" width="611" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Investigation findings in ATTR. Sural nerve biopsy demonstrating typical features of amyloidosis. (A) Severe reduction in myelinated and unmyelinated nerve fibre density with evidence of active degeneration (black arrowheads); amyloid deposition is observed in endoneural blood vessels, resulting in thickened vessels walls (black arrow), toluidine blue; scale bar=0.05 mm; (B, C) Amyloid deposits in the endoneurial blood vessel wall (blue arrowheads), Congo red-stained frozen sections. (B) Immunofluorescence with Texas red filter and (C) transmitted light. Scale bars=0.1 mm. (D, E) Technetium-99m-pyrophosphate scintigraphy in hereditary transthyretin demonstrating cardiac uptake compared with surrounding tissues with a heart to contralateral lung ratio of 2.1 (normal &lt;1.5). ATTR, transthyretin amyloidosis.</p></figcaption></figure><p>Sural nerve biopsy (<a href="#F2" class="usa-link">figure 2A–C</a>) has been traditionally used for confirming ATTRv-PN and for excluding other aetiologies, with a sensitivity of up to 86%.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> The patchy distribution of amyloid deposits may limit diagnostic utility, potentially requiring repeated nerve biopsies or biopsies of different organs.<a href="#R44" class="usa-link" aria-describedby="R44"><sup>44</sup></a> MR neurography,<a href="#R45" class="usa-link" aria-describedby="R45"><sup>45</sup></a> peripheral nerve ultrasound<a href="#R46" class="usa-link" aria-describedby="R46"><sup>46</sup></a> and whole-body 18F-florbetapir positron emission tomography/MRI imaging<a href="#R47" class="usa-link" aria-describedby="R47"><sup>47</sup></a> are promising techniques for detecting early nerve dysfunction and for targeting sites for biopsy when clinical suspicion remains high.</p>
<p>Skin biopsy may be of utility in early diagnosis of neuropathy, disclosing reduced intraepidermal nerve fibre density and Congo red positive amyloid deposits.<a href="#R48" class="usa-link" aria-describedby="R48"><sup>48</sup></a> Confocal corneal microscopy is an emerging technique for detecting small-fibre neuropathy and represents a non-invasive alternative. Corneal nerve fibre length (CNFL) is shorter in ATTRv and correlates with autonomic, clinical and neurophysiological measures of large-fibre neuropathy.<a href="#R49" class="usa-link" aria-describedby="R49"><sup>49</sup></a> Additionally, CNFL has no floor effect when compared with neurophysiological testing and intraepidermal nerve fibre density measurements.</p>
<p>Identification of a TTR gene mutation is strongly suggestive of ATTRv if the neurological phenotype and investigations are concordant, including positive cardiac uptake on 99 m Tc-PYP, 99 m Tc-DPD or HMDP scintigraphy with negative monoclonal gammopathy and general neuropathy screen (<a href="#F3" class="usa-link">figure 3</a>).<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> TTR mutations can be excluded or established on genetic testing, as sequence analysis identifies &gt;99% of pathogenic variants, with updated lists of TTR mutations and phenotypes reported in an online database (<a href="http://www.amyloidosismutations.com/mut-attr.php" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.amyloidosismutations.com/mut-attr.php</a>). Diagnostic practices may vary across countries, and pathological diagnosis remains the gold standard. Genetic testing is required to differentiate between ATTRwt and ATTRv.</p>
<figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9148983_jnnp-2021-327909f03.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e94a/9148983/05de0be24d61/jnnp-2021-327909f03.jpg" loading="lazy" height="354" width="633" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Diagnostic algorithm for ATTR polyneuropathy. Tissue biopsy may include a target organ such as nerve, heart, bone marrow or skin, or an ‘off-target’ biopsy such as salivary gland or abdominal fat pad aspirate. <sup>$</sup>Depending on availability; IHC and LD-MS are important for amyloid fibril typing. Bone scintigraphy may be semiquantitatively graded relative to rib uptake with the following grades: grade 0, no uptake and normal bone scan; grade 1, uptake less than rib uptake; grade 2, uptake equal to rib uptake; and grade 3, uptake greater than rib uptake with mild or absent rib uptake abnormalities. Echo and CMR are important investigations for detecting cardiac amyloid disease. ATTR, transthyretin amyloidosis; ATTR-PN, transthyretin amyloidosis–polyneuropathy; CMR, cardiac MRI; CTS, carpal tunnel syndrome; Echo, echocardiogram; IHC, immunohistochemistry; LD-MS, laser dissection–mass spectrometry; MGUS, monoclonal gammopathy of uncertain significance; TTR, transthyretin.</p></figcaption></figure><p>Once amyloid deposition is confirmed histologically, amyloid protein typing is essential to guide management. Immunohistochemical stains can be used, although amyloid precursor protein is identified in only 30% of cases.<a href="#R50" class="usa-link" aria-describedby="R50"><sup>50</sup></a> Mass spectrometry of tissue specimens, derived by laser microdissection, can accurately type the amyloid precursor protein with a sensitivity of 80% in cases where immunohistochemical staining was unrevealing.<a href="#R50" class="usa-link" aria-describedby="R50"><sup>50</sup></a>
</p>
<p>99 m Tc-PYP and 99 m Tc-DPD scintigraphy (<a href="#F2" class="usa-link">figure 2D, E</a>) demonstrate ATTR amyloid deposition in the myocardium with high sensitivity, specificity and positive predictive value (&gt;99%) when there is no concurrent monoclonal gammopathy on serum and urine electrophoresis or immunofixation, and in the absence of serum-free light chains.<a href="#R51" class="usa-link" aria-describedby="R51"><sup>51</sup></a> Consequently, non-biopsy diagnosis of ATTR-CM amyloidosis is now possible when there is considerable cardiac bone scintigraphy uptake (grade 2 or 3) and absence of monoclonal protein (<a href="#F3" class="usa-link">figure 3</a>). In cases where pathological TTR mutations coexist with monoclonal gammopathy of uncertain significance, neuropathy could result from either ATTRv or light-chain amyloidosis (AL). Pathological confirmation with fibril typing is essential, preferably by mass spectrometry (<a href="#F3" class="usa-link">figure 3</a>).<a href="#R51" class="usa-link" aria-describedby="R51"><sup>51</sup></a>
</p>
<p>Plasma neurofilament light chain (NfL) is emerging as a useful prognostic biomarker in ATTR-PN, demonstrating a fourfold increase and correlating with disease severity.<a href="#R52" class="usa-link" aria-describedby="R52">52 52 53 53 54 54</a> NfL may discriminate between asymptomatic Val30Met mutation carriers and ATTR-PN in early disease.<a href="#R53" class="usa-link" aria-describedby="R53"><sup>53</sup></a> A significant reduction of NfL levels was reported in patients with ATTR-PN treated with gene silencing therapies, correlating with an improvement in the neuropathy impairment score.<a href="#R54" class="usa-link" aria-describedby="R54"><sup>54</sup></a>
</p></section><section id="s5-2"><h3 class="pmc_sec_title">Diagnostic approach for ATTR neuropathy</h3>
<p>A putative diagnostic algorithm for ATTRv-PN is depicted in <a href="#F4" class="usa-link">figure</a> 3. In all patients presenting with polyneuropathy, particularly with small fibre or AN, we recommend a review of amyloid red flag symptoms, such as the presence of bilateral CTS, cardiomyopathy or pacemaker insertion, along with consideration of ethnicity and family history (<a href="#F3" class="usa-link">figure 3</a>). It is essential to consider amyloidosis in these scenarios to shorten diagnostic delays and prevent misdiagnosis. As ATTRv is now treatable, we suggest a low threshold for early TTR gene testing (<a href="#F3" class="usa-link">figure 3</a>).</p>
<figure class="fig xbox font-sm" id="F4"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9148983_jnnp-2021-327909f04.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e94a/9148983/a4669dfbf136/jnnp-2021-327909f04.jpg" loading="lazy" height="304" width="620" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanisms by which TTR mutants exert pathogenesis and therapeutic strategies for ATTRv. TTR is predominantly produced by the liver. The conversion of TTR tetramer into insoluble amyloid fibrils is a multistep dynamic process, with dissociation of TTR tetramers into misfolded monomers being the rate-limiting step for the formation of amyloid fibrils. TTR gene mutations destabilise quaternary and tertiary TTR structures and induce thermodynamic instability, resulting in the formation of misfolded monomers. Amyloid fibril formation occurs by nucleation-dependent polymerisation and is influenced by a variety of physiological factors. Therapeutic strategies aimed at different stages of amyloid formation have shown efficacy in ATTRv. ATTRv, hereditary transthyretin amyloidosis; TTR, transthyretin.</p></figcaption></figure><p>If a TTR gene variant is detected in cases with no family history, a tissue diagnosis is required. Practice varies across countries and with different phenotypical expression, but may include abdominal fat pad aspirate, skin, salivary gland, nerve or other target organ biopsies. Amyloid protein typing by immunohistochemistry or preferably laser dissection–mass spectrometry is critical, particularly in the setting of a coincidental paraprotein (<a href="#F3" class="usa-link">figure 3</a>). Occasionlly, amyloid is identified incidentally on a diagnostic nerve biospy. In this circumstance, typing of the amyloid fibril is critical, as while more commonly AL, ATTRv is a possibility and should prompt gene testing. If local laboratories are not able to confidently type the fibril, we recommend that tissue be referred to a specialised laboratory for fibril typing. Early gene testing may help to guide typing and improve time to diagnosis.</p>
<p>In an individual with typical neuropathy and biopsy-proven family history of ATTRv, gene testing should be performed as an initial investigation (<a href="#F3" class="usa-link">figure 3</a>). If a TTR variant is identified, a 99m-Tc-DPD or 99m-Tc-PYP bone scan may be performed as the next diagnostic investigation. ATTR may be diagnosed without the need for tissue biopsy, if grade 2 or 3 scintigraphic uptake abnormalities are identified and if echocardiographic/cardiac MRI criteria are satisfied, and a paraprotein is not identified on complete monoclonal gammopathy testing (serum and urine electrophoresis, immunofixation and serum-free light chains). For many clinical trials and medicine regulators, biopsy confirmation may be required. If bone scintigraphy, echocardiogram or cardiac MRI criteria are not met, tissue biopsy is required for diagnosis (<a href="#F3" class="usa-link">figure 3</a>). TTR gene mutations may coexist with other neuropathy-causing diseases, especially in older patients, such as diabetes mellitus, and in this circumstance, a nerve biospy should be considered to confirm that the neuropathy is secondary to amyloidosis. It should be stressed that additional diagnostic approaches have been propsoed and are discussed in detail elsewhere.<a href="#R55" class="usa-link" aria-describedby="R55"><sup>55</sup></a>
</p></section></section><section id="s6"><h2 class="pmc_sec_title">Pathogenesis of ATTRv</h2>
<section id="s6-1"><h3 class="pmc_sec_title">TTR amyloid fibril formation</h3>
<p>The conversion of TTR tetramer into insoluble amyloid fibrils is a multistep dynamic process (<a href="#F4" class="usa-link">figure 4</a>). Dissociation of TTR tetramer into misfolded monomers appears to be a rate-limiting step for formation of amyloid fibrils and other aggregate morphologies.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> TTR gene mutations destabilise quaternary and tertiary TTR structures and induce thermodynamic instability, thereby favouring formation of misfolded monomers.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4 16</sup></a> These destabilising effects impact the cell’s efficiency at degrading and secreting mutant TTR, thereby modulating disease severity. However, it must be noted that TTR amyloid deposition can occur without destabilising mutations, as is observed in ATTRwt. Further, wild-type TTR is frequently identified in amyloid deposits in patients with ATTRv, in particular in late-onset ATTRV30M cases and in cardiac tissues after liver transplantation.<a href="#R56" class="usa-link" aria-describedby="R56"><sup>56 57</sup></a>
</p>
<p>Amyloid fibril formation occurs by nucleation-dependent polymerisation, whereby formation of the oligomeric high-energy quaternary structures is required prior to aggregation of misfolded monomers.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> Subsequently, deposition of TTR monomers proceeds by spontaneous downhill polymerisation, and C-terminal TTR protein fragments produced by trypsin proteolysis are likely to promote TTR aggregation.<a href="#R58" class="usa-link" aria-describedby="R58"><sup>58 59</sup></a> The formation of amyloid fibrils is influenced by several factors including temperature, pH, presence of cosolvent precursor protein concentration, abnormal proteolysis and proteostatic mechanisms, oxidative stress, shear stress, pH alterations and interactions with extracellular matrix components, such as sulfated glycosaminoglycans.<a href="#R60" class="usa-link" aria-describedby="R60"><sup>60 61</sup></a>
</p></section><section id="s6-2"><h3 class="pmc_sec_title">Toxicity of amyloid fibrils</h3>
<p>Amyloid fibrils may cause tissue damage by compression, obstruction, cellular toxicity or disturbance of local blood circulation.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> Vascular deposition may be a pathological feature of systemic amyloidosis, resulting in atypical amyloid presentations, such as jaw claudication and myocardial ischaemia in the absence of atherosclerotic disease. Cellular toxicity is mediated by low-molecular-weight oligomers and protofibrils,<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> by activation of the receptor for advanced glycation end products, resulting in endoplasmic reticulum stress, caspase-dependent apoptosis and activation of extracellular signal-regulated kinases with disruption of cellular differentiation.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> Induction of calcium influx and increased oxidative stress represent additional pathogenic mechanisms by which oligomers and protofibrils exert toxic effects. Furthermore, direct fibril ultrastructural damage has been identified by a recent electron microscopic study which demonstrated amyloid fibril maturation from prefibrillar and rounded structures arising within the amorphous extracellular material. Fibril maturation resulted in distortion of the surrounding Schwann cell basement and cytosolic membranes, leading to atrophy of Schwann cells.<a href="#R62" class="usa-link" aria-describedby="R62"><sup>62</sup></a>
</p></section></section><section id="s7"><h2 class="pmc_sec_title">Disease-modifying therapies for ATTRv</h2>
<p>Strategies for treating ATTRv are directed at reducing the production and deposition of the pathogenic TTR.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> The following therapeutic approaches have shown efficacy: (1) targeting of TTR production, (2) stabilisation of TTR tetramers and (3) degradation of TTR amyloid deposits. <a href="#SP1" class="usa-link">Online supplemental table 1</a> provides a summary of clinical trials in ATTRv.</p>
<section class="sm xbox font-sm" id="SP1"><div class="caption p"><span>Supplementary data</span></div>
<p>
<a href="/articles/instance/9148983/bin/jnnp-2021-327909supp001.pdf" class="usa-link" id="SS1">jnnp-2021-327909supp001.pdf</a><sup> (138.8KB, pdf) </sup>
</p></section><section id="s7-1"><h3 class="pmc_sec_title">Liver transplantation</h3>
<p>Liver transplantation is effective at ameliorating the course of ATTRv<a href="#R63" class="usa-link" aria-describedby="R63"><sup>63</sup></a> by replacing the mutated TTR gene with wild type, resulting in marked reduction of variant TTR serum concentrations and regression of amyloid deposition.<a href="#R64" class="usa-link" aria-describedby="R64"><sup>64</sup></a> The survival rates of 5 and 10 years are 85% and 73%, respectively,<a href="#R65" class="usa-link" aria-describedby="R65"><sup>65</sup></a> with greater effects evident in Val30Met ATTR-PN. Early-onset disease, shorter disease duration, better nutritional status prior to transplantation and improved perioperative management have been associated with improved survival.<a href="#R65" class="usa-link" aria-describedby="R65"><sup>65 66</sup></a> No significant effects were reported in late-onset disease ATTRv, although women with late-onset disease had a longer survival.<a href="#R66" class="usa-link" aria-describedby="R66"><sup>66</sup></a> The outcome after liver transplantation is better for live compared with cadaveric donor grafts.<a href="#R67" class="usa-link" aria-describedby="R67"><sup>67</sup></a>
</p>
<p>Liver transplantation is associated with improvement or stabilisation in peripheral neuropathy and AN.<a href="#R16" class="usa-link" aria-describedby="R16">16 20 63 65</a> While liver transplantation is an accepted therapeutic option, limitations include procedure-related morbidity and mortality (~10%), requirement for donors and long-term immunosuppression, along with lack of equivalent efficacy for non-Val30Met ATTRv. Liver transplantation fails to reduce TTR production in the choroid plexus and retinal pigment cells, potentially leading to development of oculoleptomeningeal disease.<a href="#R68" class="usa-link" aria-describedby="R68"><sup>68</sup></a> Domino-liver transplantation was used to overcome organ shortage, but recipients developed polyneuropathy about 10 years after intervention.<a href="#R69" class="usa-link" aria-describedby="R69"><sup>69</sup></a> Nowadays, liver transplantation could be considered in patients refractory or intolerant to other pharmacological options, or when other treatment options are unavailable.</p></section></section><section id="s8"><h2 class="pmc_sec_title">TTR tetramer stabilisers</h2>
<section id="s8-1"><h3 class="pmc_sec_title">Diflunisal</h3>
<p>Diflunisal is an oral non-steroidal anti-inflammatory drug that inhibits amyloid fibril formation by binding to the T4 binding sites of TTR protein.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> Diflunisal led to stabilisation of variant TTR tetramer and reduction of protein aggregation.<a href="#R70" class="usa-link" aria-describedby="R70"><sup>70</sup></a> A phase III trial demonstrated efficacy of diflunisal (250 mg two times per day) in ATTRv-PN (Val30Met and non-Val30Met mutations), with sustained slowing of neuropathy progression and improvement in quality of life.<a href="#R71" class="usa-link" aria-describedby="R71"><sup>71</sup></a>
</p>
<p>A long-term open-label study demonstrated stabilisation in peripheral neuropathy, although the alteration in rate of decline was not significant.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> Separately, cardiac dysfunction was reduced by diflunisal. Significant side effects were reported, including gastrointestinal symptoms and transitory renal function impairment.<a href="#R72" class="usa-link" aria-describedby="R72"><sup>72</sup></a>
</p></section><section id="s8-2"><h3 class="pmc_sec_title">Tafamidis</h3>
<p>Tafamidis is an oral TTR–tetramer protein stabiliser which reduces TTR–variant protein aggregation by associating with the T4 binding site.<a href="#R73" class="usa-link" aria-describedby="R73"><sup>73</sup></a> While tafamidis failed to meet the coprimary endpoints (Neuropathy Impairment Score–Lower Limbs (NIS-LL) and Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) total scores),<a href="#R74" class="usa-link" aria-describedby="R74"><sup>74</sup></a> a greater proportion of tafamidis-treated patients were classified as NIS-LL responders and reported preserved total qulaity of life (TQOL), suggesting clinical efficacy. An open-label extension study disclosed stabilisation of NIS-LL and TQOL scores,<a href="#R74" class="usa-link" aria-describedby="R74"><sup>74</sup></a> with greater preservation of neurological function in patients initiated at earlier stages of disease progression. The clinical benefit was associated with stabilisation of plasma TTR levels. Efficacy and safety of tafamidis was also reported in a small cohort of Japanese patients with ATTRv (Val30Met and non-Val30Met mutations).<a href="#R75" class="usa-link" aria-describedby="R75"><sup>75</sup></a> A long-term extension study in mild ATTR-PN reported a sustained delay in neuropathy progression and long-term preservation of nutritional status.<a href="#R76" class="usa-link" aria-describedby="R76"><sup>76</sup></a> No clinical effects were evident in patients with ATTRv with advanced disease.<a href="#R77" class="usa-link" aria-describedby="R77"><sup>77</sup></a> Tafamidis reduced mortality risk in early (91%) and late (82%) affected patients compared with untreated patients.<a href="#R78" class="usa-link" aria-describedby="R78"><sup>78</sup></a> Greater baseline neurological dysfunction appears to be an independent predictor of disease progression, and early treatment was associated with slower rates of disease progression.<a href="#R79" class="usa-link" aria-describedby="R79"><sup>79</sup></a> The European medicine agency approved tafamidis in 2011 for stage 1 ATTRv, although 30%–40% of the patients were considered non-responders.</p>
<p>A recent multicentre phase III trial established efficacy of tafamidis in ATTR-CM,<a href="#R80" class="usa-link" aria-describedby="R80"><sup>80</sup></a> with lower mortality, cardiovascular-related hospitalisations, improved quality of life and functional capacity. A subsequent long-term study reaffirmed the clinical effectiveness.<a href="#R81" class="usa-link" aria-describedby="R81"><sup>81</sup></a> Tafamidis was approved in 2020 for treating ATTRwt and ATTRv-related cardiomyopathy.</p></section></section><section id="s9"><h2 class="pmc_sec_title">Other TTR stabilisers</h2>
<section id="s9-1"><h3 class="pmc_sec_title">Acoramidis</h3>
<p>AG10 is a novel and selective oral TTR stabiliser developed for treatment of ATTR.<a href="#R82" class="usa-link" aria-describedby="R82"><sup>82</sup></a> Recent studies demonstrated the safety and biological efficacy of AG10.<a href="#R82" class="usa-link" aria-describedby="R82"><sup>82 83</sup></a> Currently, phase III trials are assessing the effectiveness of AG10 in ATTR-CM (<a href="https://clinicaltrials.gov/ct2/show/NCT03860935" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03860935</a>) and ATTR-PN (<a href="https://clinicaltrials.gov/ct2/show/NCT04882735" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04882735</a>).</p>
<p>Green tea extract, which contains the catechin epigallocatechin-3-gallate (EGCG), is an inhibitor of amyloid fibril formation and disrupts fibril aggregation.<a href="#R84" class="usa-link" aria-describedby="R84"><sup>84</sup></a> Orally administered EGCG was associated with stabilisation of cardiac function in ATTRwt amyloidosis.<a href="#R85" class="usa-link" aria-describedby="R85"><sup>85</sup></a> Utility of EGCG in ATTRv neuropathy remains unresolved, although high CNS bioavailability makes this an interesting target for potential multidrug therapies. Tolcapone, a TTR stabiliser that effectively crosses the blood–brain barrier, is being investigated as a potential treatment for ATTRv-LA.<a href="#R86" class="usa-link" aria-describedby="R86"><sup>86</sup></a>
</p></section></section><section id="s10"><h2 class="pmc_sec_title">TTR fibril removal</h2>
<p>Combination therapy with <em>doxycycline</em>, which interferes with formation of TTR amyloid fibrils,<a href="#R87" class="usa-link" aria-describedby="R87"><sup>87</sup></a> and tauroursodeoxycholic acid (TUDCA), a biliary acid that reduces non-fibrillary TTR aggregation, was reported to exert synergistic effect in the TTR mouse model (Val30Met).<a href="#R88" class="usa-link" aria-describedby="R88"><sup>88</sup></a> Stabilisation of neurological and cardiac function over 12 months was reported by combining doxycycline (200 mg/day) and TUDCA (250 mg three times per day).<a href="#R89" class="usa-link" aria-describedby="R89"><sup>89</sup></a> Monoclonal antibodies developed against serum amyloid P (SAP) (constituent that contributes to aggregate stability) and TTR (including PRX004) have disclosed mixed results. While initial murine and human studies of anti-SAP led to clearance of amyloid tissue deposits, ongoing clinical trials have been suspended.<a href="#R90" class="usa-link" aria-describedby="R90"><sup>90–92</sup></a> A recent small phase I trial of PRX004 demonstrated safety and tolerability of anti-TTR treatment while reducing progression of neuropathy and cardiac disease (<a href="https://ir.prothena.com/static-files/ee65ab75-2e8b-4eae-989b-3de7c7bd9149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ir.prothena.com/static-files/ee65ab75-2e8b-4eae-989b-3de7c7bd9149</a>). Phase II studies of anti-TTR monoclonal antibodies are ongoing.</p></section><section id="s11"><h2 class="pmc_sec_title">Gene therapies</h2>
<p>Gene silencing therapies using antisense oligonucleotides (ASOs) or siRNAs have emerged as safe and effective strategies for treating ATTR. The two main gene silencing compounds that have undergone extensive clinical assessment in ATTR include inotersen (ASO) and patisiran (siRNA) and have been approved for treating stage 1 and 2 ATTRv.</p>
<section id="s11-1"><h3 class="pmc_sec_title">Antisense oligonucleotides</h3>
<p>
<em>Inotersen</em> is a short ASO that selectively binds to the complementary RNA, preventing RNA translation and protein expression. Preclinical studies established that TTR-specific ASOs suppress production of TTR mRNA by hepatocytes, with reduction of serum TTR protein levels in transgenic mouse models (Ile84Ser).<a href="#R93" class="usa-link" aria-describedby="R93"><sup>93</sup></a> Subsequently, an ASO (ISIS-TTR<sub>RX</sub>) binding to the 3’ non-translated portion of the human TTR mRNA was developed and shown to significantly decrease liver mRNA and plasma TTR protein levels in animal models.<a href="#R94" class="usa-link" aria-describedby="R94"><sup>94</sup></a> A first in human phase I clinical trial established the safety and biological efficacy of ISIS-TTR<sub>RX</sub>.<a href="#R94" class="usa-link" aria-describedby="R94"><sup>94</sup></a>
</p>
<p>The pivotal phase III (NEURO-TTR) study established efficacy of inotersen (300 mg/week) in adult-onset patients with stage 1 (ambulatory) and stage 2 (ambulatory with assistance) ATTRv-PN.<a href="#R95" class="usa-link" aria-describedby="R95"><sup>95</sup></a> The decline in modified NIS+7 (mNIS+7) and Norfolk QOL-DN were significantly reduced by inotersen, and effectiveness was independent of disease stage, TTR mutation or presence of cardiomyopathy. Thrombocytopenia and glomerulonephritis were evident in 3% of patients. An open-label extension study confirmed clinical effectiveness of inotersen, including in patients switching from placebo,<a href="#R96" class="usa-link" aria-describedby="R96"><sup>96 97</sup></a> associated with significant reductions in serum TTR levels.<a href="#R95" class="usa-link" aria-describedby="R95"><sup>95 97</sup></a>
</p>
<p>Additional analysis of the NEURO-TTR trial revealed stabilisation or improvement in sensory, motor and autonomic symptoms.<a href="#R98" class="usa-link" aria-describedby="R98"><sup>98</sup></a> Analysis of modified NIS+7 components and lower limb function revealed effects on muscles weakness, sensation and heat pain perception as well as lower limb reflexes.<a href="#R99" class="usa-link" aria-describedby="R99"><sup>99</sup></a> Improvement in lower limb function and summated mNIS+7 neurophysiological subscores (five nerves), particularly ulnar nerve motor amplitudes, were reported.</p>
<p>The safety and efficacy of inotersen was also reported in ATTR-CM.<a href="#R100" class="usa-link" aria-describedby="R100"><sup>100</sup></a> Stabilisation of cardiac disease, as measured by left ventricular wall thickness and mass, as well as 6 min walk test and echocardiographic global longitudinal strain, was reported in patients with moderate-to-severe restrictive cardiomyopathy. An open-label trial is under way to assess tolerability and efficacy of inotersen in ATTR-CM (<a href="https://clinicaltrials.gov/ct2/show/NCT03702829" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03702829</a>). As only a small fraction (&lt;1%) of ASO cross the blood–brain barrier, inotersen is unlikely to have utility in leptomeningeal amyloidosis.</p>
<p>In order to improve the safety and dosing profile of inotersen, the ASO has been ligand-conjugated to allow hepatic receptor uptake.<a href="#R101" class="usa-link" aria-describedby="R101"><sup>101</sup></a> A phase I study (<a href="http://clinicaltrials.gov/show/NCT03728634" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03728634</a>) has confirmed improved potency and safety of eplontersen (AKCEA-TTR-LRx), with no serious adverse events noted.<a href="#R101" class="usa-link" aria-describedby="R101"><sup>101</sup></a> Phase III studies are now under way in both ATTRv-PN (<a href="https://clinicaltrials.gov/ct2/show/NCT04136184" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04136184</a>) and ATTR-CM (<a href="https://clinicaltrials.gov/ct2/show/NCT04136171" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04136171</a>).</p></section><section id="s11-2"><h3 class="pmc_sec_title">Small interfering RNAs</h3>
<p>Gene expression can be modulated by siRNA (21–23 nucleotide long double-stranded RNA molecules) which target and cleaves complementary mRNAs. The siRNAs are synthetically produced and introduced into the cell, leading to ‘knockdown’ of target gene expression. Patisiran is a TTR-specific siRNA which has exhibited efficacy in preclinical and clinical studies. Targeting of the 3′ untranslated region of TTR mRNA in primates resulted in 90% reduction of TTR at day 14 postinfusion and &gt;70% reduction at day 28.<a href="#R102" class="usa-link" aria-describedby="R102"><sup>102</sup></a> A phase I study in mild–moderate ATTR-PN resulted in a dose-dependent reduction in serum TTR protein levels.<a href="#R102" class="usa-link" aria-describedby="R102"><sup>102</sup></a> The duration of supression was greater with higher doses, while TTR knockdown observed in humans was identical to that seen in non-human primates.</p>
<p>The APOLLO trial established clinical efficacy of patisiran (0.3 mg/kg infused three times per week) in ATTRv.<a href="#R103" class="usa-link" aria-describedby="R103"><sup>103</sup></a> Improvement in mNIS7+ scores at 18 months was reported, with clincial effects evident 9 months after treatment initiation. The clinical benefits were evident irrespective of the degree of peripheral neuropathy and correlated with TTR protein reduction. Improvements in AN, quality of life, gait speed, nutritional status and cardiac function were also seen. Patisiran was safe with mild–moderate infusion-related reactions reported.</p>
<p>An open-label extension study reported sustained long-term clinical effectiveness of patisiran.<a href="#R104" class="usa-link" aria-describedby="R104"><sup>104</sup></a> Specifically, improvement in mNIS7+ was maintained at 12 months, as were improvements in AN, quality of life, nutritional status and overall disability. Switching from placebo to patisiran also resulted in an improvement or stabilisation of clinical parameters. No long-term safety issues were identified with patisiran treatment. The clinical benefits were evident across all measures of quality of life, including physical functioning, activities of daily living, and autonomic and small-fibre neuropathy symptoms, as well as pain perception.<a href="#R105" class="usa-link" aria-describedby="R105"><sup>105</sup></a>
</p>
<p>A second-generation siRNA (vutrisiran) is under investigation for treatement of ATTRv. Like patisiran, it contains an siRNA that targets a highly conserved mRNA sequence across all known TTR variants (including wild-type TTR).<a href="#R106" class="usa-link" aria-describedby="R106"><sup>106</sup></a> Subcutaneously administered vutrisiran (5–300 mg) led to a dose-dependent reduction in TTR, with mean TTR reduction varying between 57% and 97%.<a href="#R106" class="usa-link" aria-describedby="R106"><sup>106</sup></a> The reduction in TTR protein levels was maintained for ≥90 days post dose. The effectiveness of vutrisiran in ATTRv-PN and ATTR-CM is currently being investigated. Like ASOs, siRNAs do not efficiently cross the blood–brain barrier and hence are unlikely to have therapeutic utility in ATTR-LA.</p></section><section id="s11-3"><h3 class="pmc_sec_title">Gene editing</h3>
<p>An alternative to mRNA target-based gene silencing strategies is the use of clustered, regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR–Cas9) system to achieve in vivo gene editing. Given that ATTR is monogenic, and knockdown of TTR has limited physiological effects, CRISPR–Cas9-mediated in vivo gene editing would seem ideal for treatment of ATTRv. Additionally, TTR is largely produced by the liver for which established targeting systems (lipid nanoparticles (LNPs)) are available. NTLA-2001 (a novel CRISPR–Cas9-based gene-editing therapy) consists of a single-guide RNA (sgRNA) targeting human TTR with a human codon-optimised mRNA sequence of <em>Streptococcus pyogenes</em> (Spy)–Cas9 protein.<a href="#R107" class="usa-link" aria-describedby="R107"><sup>107</sup></a> The proprietary LNP enables targeted delivery of NTLA-2001 to hepatocytes by endocytosis through low-density lipoprotein receptors,<a href="#R108" class="usa-link" aria-describedby="R108"><sup>108</sup></a> and once in the cell, the Spy–Cas9 mRNA is translated to a Spy–Cas9 endonuclease, resulting in the formation of the Cas9–sgRNA ribonucleoprotein complex that enters into the nucleus and removes the mutant TTR gene.<a href="#R109" class="usa-link" aria-describedby="R109"><sup>109</sup></a> Intravenous infusion of NTLA-2001 was shown to reduce TTR protein levels by 95% after a single infusion in animal studies.<a href="#R107" class="usa-link" aria-describedby="R107"><sup>107</sup></a>
</p>
<p>A first-in-human study demonstrated a dose-dependent reduction of serum TTR protein levels in ATTRv-PN, after a single infusion of NTLA-2001.<a href="#R109" class="usa-link" aria-describedby="R109"><sup>109</sup></a> No serious adverse events were recorded, although three patients reported mild infusion related side effects. Further trials of CRISPR–Cas9-based therapeutic approaches are warranted to determine clinical efficacy and safety.</p></section></section><section id="s12"><h2 class="pmc_sec_title">Summary</h2>
<p>This review outlines the recent advances in understanding of the pathogenesis, clinical phenotypes, diagnosis and treatment of ATTRv. Novel treatment strategies are revolutionising patient outcomes, underscoring the importance of early diagnosis. The ideal timing of treatment initiation, use of combination therapies, potential long-term complications of TTR depletion, and the treatment of sequestered leptomeningeal and occular sites are issues that need to be further addressed. Recognition of the heterogeneous clinical presentations of amyloidosis and diagnostic strategies is essential for all clinicians, with the potential to greatly impact patient outcomes. It is likely that novel gene-editing therapies will herald a new era for treating protein misfolding diseases. Moreover, epigenetic factors and mitochondrial polymorphism are additional areas that may be approached to modify disease outcomes.<a href="#R110" class="usa-link" aria-describedby="R110"><sup>110</sup></a>
</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Twitter:</strong> @jnnp_bmj</p></div>
<div class="fn p" id="fn2"><p><strong>Contributors:</strong> AC and SV planned the review and wrote the initial draft. PJD, MdC, MK, MMR and MCK provided critical review, edited the manuscript and approved the final version.</p></div>
<div class="fn p" id="fn3"><p><strong>Funding:</strong> SV gratefully acknowledges funding support from the National Health and Medical Research Council (NHMRC) of Australia (project grant numbers 510233, 1024915 and 1055778; program grant number 1132524; dementia research team grant number 1095127; and Partnership Project number 1153439) and the Motor Neuron Disease Research Institute of Australia. MCK was supported by a NHMRC Practitioner Fellowship (number 1156093).</p></div>
<div class="fn p" id="fn4"><p><strong>Competing interests:</strong> Author MMR has consulted for Alnylam, IONIS and AKCEA.</p></div>
<div class="fn p" id="fn5"><p><strong>Provenance and peer review:</strong> Commissioned; externally peer reviewed.</p></div>
<div class="fn p" id="fn6"><p><strong>Supplemental material:</strong> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></div>
</div></section><section id="sec28"><h2 class="pmc_sec_title">Ethics statements</h2>
<section id="sec29"><h3 class="pmc_sec_title">Patient consent for publication</h3>
<p>Not applicable.</p></section><section id="sec30"><h3 class="pmc_sec_title">Ethics approval</h3>
<p>This study does not involve human participants.</p></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>
Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry
2015;86:1036–43. 10.1136/jnnp-2014-308724
</cite> [<a href="https://doi.org/10.1136/jnnp-2014-308724" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25604431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Transthyretin%20(ATTR)%20amyloidosis:%20clinical%20spectrum,%20molecular%20pathogenesis%20and%20disease-modifying%20treatments&amp;volume=86&amp;publication_year=2015&amp;pages=1036-43&amp;pmid=25604431&amp;doi=10.1136/jnnp-2014-308724&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>
Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of amyloidosis (Isa) Nomenclature Committee. Amyloid
2020;27:217–22. 10.1080/13506129.2020.1835263
</cite> [<a href="https://doi.org/10.1080/13506129.2020.1835263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33100054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Amyloid%20nomenclature%202020:%20update%20and%20recommendations%20by%20the%20International%20Society%20of%20amyloidosis%20(Isa)%20Nomenclature%20Committee&amp;volume=27&amp;publication_year=2020&amp;pages=217-22&amp;pmid=33100054&amp;doi=10.1080/13506129.2020.1835263&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA
2020;324:79–89. 10.1001/jama.2020.5493
</cite> [<a href="https://doi.org/10.1001/jama.2020.5493" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32633805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Systemic%20amyloidosis%20recognition,%20prognosis,%20and%20therapy:%20a%20systematic%20review&amp;volume=324&amp;publication_year=2020&amp;pages=79-89&amp;pmid=32633805&amp;doi=10.1001/jama.2020.5493&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>
Blake CC, Geisow MJ, Swan ID, et al. Strjcture of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol
1974;88:1–12. 10.1016/0022-2836(74)90291-5
</cite> [<a href="https://doi.org/10.1016/0022-2836(74)90291-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4216640/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Biol&amp;title=Strjcture%20of%20human%20plasma%20prealbumin%20at%202-5%20A%20resolution.%20A%20preliminary%20report%20on%20the%20polypeptide%20chain%20conformation,%20quaternary%20structure%20and%20thyroxine%20binding&amp;volume=88&amp;publication_year=1974&amp;pages=1-12&amp;pmid=4216640&amp;doi=10.1016/0022-2836(74)90291-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>
Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve regeneration. J Neurochem
2007;103:831–9. 10.1111/j.1471-4159.2007.04828.x
</cite> [<a href="https://doi.org/10.1111/j.1471-4159.2007.04828.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17897357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurochem&amp;title=Transthyretin%20enhances%20nerve%20regeneration&amp;volume=103&amp;publication_year=2007&amp;pages=831-9&amp;pmid=17897357&amp;doi=10.1111/j.1471-4159.2007.04828.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>
Brouillette J, Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging
2008;29:1721–32. 10.1016/j.neurobiolaging.2007.04.007
</cite> [<a href="https://doi.org/10.1016/j.neurobiolaging.2007.04.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17512093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurobiol%20Aging&amp;title=Transthyretin:%20a%20key%20gene%20involved%20in%20the%20maintenance%20of%20memory%20capacities%20during%20aging&amp;volume=29&amp;publication_year=2008&amp;pages=1721-32&amp;pmid=17512093&amp;doi=10.1016/j.neurobiolaging.2007.04.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>
Minnella AM, Rissotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes
2021;12. 10.3390/genes12070955. [Epub ahead of print: 22 06 2021].
</cite> [<a href="https://doi.org/10.3390/genes12070955" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8304974/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34206500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes&amp;title=Ocular%20involvement%20in%20hereditary%20amyloidosis&amp;volume=12&amp;publication_year=2021&amp;pmid=34206500&amp;doi=10.3390/genes12070955&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>
Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis. Semin Neurol
2019;39:578–88. 10.1055/s-0039-1688994
</cite> [<a href="https://doi.org/10.1055/s-0039-1688994" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31639841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Neurol&amp;title=Neuropathy%20associated%20with%20systemic%20amyloidosis&amp;volume=39&amp;publication_year=2019&amp;pages=578-88&amp;pmid=31639841&amp;doi=10.1055/s-0039-1688994&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>
Inês M, Coelho T, Conceição I, et al. Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study. Neuroepidemiology
2018;51:177–82. 10.1159/000490553
</cite> [<a href="https://doi.org/10.1159/000490553" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30153683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuroepidemiology&amp;title=Epidemiology%20of%20transthyretin%20familial%20amyloid%20polyneuropathy%20in%20Portugal:%20a%20nationwide%20study&amp;volume=51&amp;publication_year=2018&amp;pages=177-82&amp;pmid=30153683&amp;doi=10.1159/000490553&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>
Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR Met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet
1994;31:351–4. 10.1136/jmg.31.5.351
</cite> [<a href="https://doi.org/10.1136/jmg.31.5.351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1049863/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8064809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Genet&amp;title=Geographical%20distribution%20of%20TTR%20Met30%20carriers%20in%20northern%20Sweden:%20discrepancy%20between%20carrier%20frequency%20and%20prevalence%20rate&amp;volume=31&amp;publication_year=1994&amp;pages=351-4&amp;pmid=8064809&amp;doi=10.1136/jmg.31.5.351&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>
Gorram F, Olsson M, Alarcon F, et al. New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid
2021;28:84–90. 10.1080/13506129.2020.1841623
</cite> [<a href="https://doi.org/10.1080/13506129.2020.1841623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33146042/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=New%20data%20on%20the%20genetic%20profile%20and%20penetrance%20of%20hereditary%20Val30Met%20transthyretin%20amyloidosis%20in%20Sweden&amp;volume=28&amp;publication_year=2021&amp;pages=84-90&amp;pmid=33146042&amp;doi=10.1080/13506129.2020.1841623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>
Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR Ala 60) in North West ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry
1995;59:45–9. 10.1136/jnnp.59.1.45
</cite> [<a href="https://doi.org/10.1136/jnnp.59.1.45" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1073600/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7608709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Familial%20amyloid%20polyneuropathy%20(TTR%20Ala%2060)%20in%20North%20West%20ireland:%20a%20clinical,%20genetic,%20and%20epidemiological%20study&amp;volume=59&amp;publication_year=1995&amp;pages=45-9&amp;pmid=7608709&amp;doi=10.1136/jnnp.59.1.45&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>
Hsieh S-T. Amyloid neuropathy with transthyretin mutations: overview and unique Ala97Ser in Taiwan. Acta Neurol Taiwan
2011;20:155–60.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/21739396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Neurol%20Taiwan&amp;title=Amyloid%20neuropathy%20with%20transthyretin%20mutations:%20overview%20and%20unique%20Ala97Ser%20in%20Taiwan&amp;volume=20&amp;publication_year=2011&amp;pages=155-60&amp;pmid=21739396&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>
Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid
2015;22:79–83. 10.3109/13506129.2014.997872
</cite> [<a href="https://doi.org/10.3109/13506129.2014.997872" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26017328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Safety%20and%20efficacy%20of%20long-term%20diflunisal%20administration%20in%20hereditary%20transthyretin%20(ATTR)%20amyloidosis&amp;volume=22&amp;publication_year=2015&amp;pages=79-83&amp;pmid=26017328&amp;doi=10.3109/13506129.2014.997872&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>
Planté-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet
2003;40:e120. 10.1136/jmg.40.11.e120
</cite> [<a href="https://doi.org/10.1136/jmg.40.11.e120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1735318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14627687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Genet&amp;title=Genetic%20study%20of%20transthyretin%20amyloid%20neuropathies:%20carrier%20risks%20among%20French%20and%20Portuguese%20families&amp;volume=40&amp;publication_year=2003&amp;pages=e120&amp;pmid=14627687&amp;doi=10.1136/jmg.40.11.e120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>
Finsterer J, Iglseder S, Wanschitz J, et al. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand
2019;139:92–105. 10.1111/ane.13035
</cite> [<a href="https://doi.org/10.1111/ane.13035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30295933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Neurol%20Scand&amp;title=Hereditary%20transthyretin-related%20amyloidosis&amp;volume=139&amp;publication_year=2019&amp;pages=92-105&amp;pmid=30295933&amp;doi=10.1111/ane.13035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>
Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology
2004;63:129–38. 10.1212/01.wnl.0000132966.36437.12
</cite> [<a href="https://doi.org/10.1212/01.wnl.0000132966.36437.12" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15249622/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Pathology%20of%20early-%20vs%20late-onset%20TTR%20Met30%20familial%20amyloid%20polyneuropathy&amp;volume=63&amp;publication_year=2004&amp;pages=129-38&amp;pmid=15249622&amp;doi=10.1212/01.wnl.0000132966.36437.12&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>
Pinto MV, Dyck PJB, Liewluck T. Neuromuscular amyloidosis: unmasking the master of disguise. Muscle Nerve
2021;64:23–36. 10.1002/mus.27150
</cite> [<a href="https://doi.org/10.1002/mus.27150" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33458861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Neuromuscular%20amyloidosis:%20unmasking%20the%20master%20of%20disguise&amp;volume=64&amp;publication_year=2021&amp;pages=23-36&amp;pmid=33458861&amp;doi=10.1002/mus.27150&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>
Kapoor M, Rossor AM, Laura M, et al. Clinical presentation, diagnosis and treatment of TTR amyloidosis. J Neuromuscul Dis
2019;6:189–99. 10.3233/JND-180371
</cite> [<a href="https://doi.org/10.3233/JND-180371" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6598024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30829617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neuromuscul%20Dis&amp;title=Clinical%20presentation,%20diagnosis%20and%20treatment%20of%20TTR%20amyloidosis&amp;volume=6&amp;publication_year=2019&amp;pages=189-99&amp;pmid=30829617&amp;doi=10.3233/JND-180371&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>
Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant
2007;7:2597–604. 10.1111/j.1600-6143.2007.01969.x
</cite> [<a href="https://doi.org/10.1111/j.1600-6143.2007.01969.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17868062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Liver%20transplantation%20for%20familial%20amyloidotic%20polyneuropathy%20(FAP):%20a%20single-center%20experience%20over%2016%20years&amp;volume=7&amp;publication_year=2007&amp;pages=2597-604&amp;pmid=17868062&amp;doi=10.1111/j.1600-6143.2007.01969.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>
Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry
2012;83:152–8. 10.1136/jnnp-2011-301299
</cite> [<a href="https://doi.org/10.1136/jnnp-2011-301299" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22228785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Natural%20history%20of%20transthyretin%20Val30Met%20familial%20amyloid%20polyneuropathy:%20analysis%20of%20late-onset%20cases%20from%20non-endemic%20areas&amp;volume=83&amp;publication_year=2012&amp;pages=152-8&amp;pmid=22228785&amp;doi=10.1136/jnnp-2011-301299&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>
Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis
2018;13:6. 10.1186/s13023-017-0726-x
</cite> [<a href="https://doi.org/10.1186/s13023-017-0726-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5773042/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29343286/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Orphanet%20J%20Rare%20Dis&amp;title=Diagnosis%20and%20management%20of%20transthyretin%20familial%20amyloid%20polyneuropathy%20in%20Japan:%20red-flag%20symptom%20clusters%20and%20treatment%20algorithm&amp;volume=13&amp;publication_year=2018&amp;pages=6&amp;pmid=29343286&amp;doi=10.1186/s13023-017-0726-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>
Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve
2007;35:116–8. 10.1002/mus.20644
</cite> [<a href="https://doi.org/10.1002/mus.20644" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16969832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Clinical%20variability%20in%20type%20I%20familial%20amyloid%20polyneuropathy%20(Val30Met):%20comparison%20between%20late-%20and%20early-onset%20cases%20in%20Portugal&amp;volume=35&amp;publication_year=2007&amp;pages=116-8&amp;pmid=16969832&amp;doi=10.1002/mus.20644&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>
Carr AS, Pelayo-Negro AL, Evans MR, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry
2016;87:620–7. 10.1136/jnnp-2015-310907
</cite> [<a href="https://doi.org/10.1136/jnnp-2015-310907" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26243339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=A%20study%20of%20the%20neuropathy%20associated%20with%20transthyretin%20amyloidosis%20(ATTR)%20in%20the%20UK&amp;volume=87&amp;publication_year=2016&amp;pages=620-7&amp;pmid=26243339&amp;doi=10.1136/jnnp-2015-310907&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>
Théaudin M, Lozeron P, Algalarrondo V, et al. Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. Eur J Neurol
2019;26:497–e436. 10.1111/ene.13845
</cite> [<a href="https://doi.org/10.1111/ene.13845" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30350904/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Neurol&amp;title=Upper%20limb%20onset%20of%20hereditary%20transthyretin%20amyloidosis%20is%20common%20in%20non-endemic%20areas&amp;volume=26&amp;publication_year=2019&amp;pages=497-e436&amp;pmid=30350904&amp;doi=10.1111/ene.13845&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>
Dohrn MF, Röcken C, De Bleecker JL, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol
2013;260:3093–108. 10.1007/s00415-013-7124-7
</cite> [<a href="https://doi.org/10.1007/s00415-013-7124-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24101130/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Diagnostic%20hallmarks%20and%20pitfalls%20in%20late-onset%20progressive%20transthyretin-related%20amyloid-neuropathy&amp;volume=260&amp;publication_year=2013&amp;pages=3093-108&amp;pmid=24101130&amp;doi=10.1007/s00415-013-7124-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>
Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry
2017;88:457–8. 10.1136/jnnp-2016-315262
</cite> [<a href="https://doi.org/10.1136/jnnp-2016-315262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5529976/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28188196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Diagnostic%20challenges%20in%20hereditary%20transthyretin%20amyloidosis%20with%20polyneuropathy:%20avoiding%20misdiagnosis%20of%20a%20treatable%20hereditary%20neuropathy&amp;volume=88&amp;publication_year=2017&amp;pages=457-8&amp;pmid=28188196&amp;doi=10.1136/jnnp-2016-315262&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>
Salvi F, Pastorelli F, Plasmati R, et al. Genotypic and phenotypic correlation in an Italian population of hereditary amyloidosis TTR-related (HA-TTR): clinical and neurophysiological AIDS to diagnosis and some reflections on misdiagnosis. Amyloid
2012;19 Suppl 1:58–60. 10.3109/13506129.2012.682187
</cite> [<a href="https://doi.org/10.3109/13506129.2012.682187" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22620967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Genotypic%20and%20phenotypic%20correlation%20in%20an%20Italian%20population%20of%20hereditary%20amyloidosis%20TTR-related%20(HA-TTR):%20clinical%20and%20neurophysiological%20AIDS%20to%20diagnosis%20and%20some%20reflections%20on%20misdiagnosis&amp;volume=19%20Suppl%201&amp;publication_year=2012&amp;pages=58-60&amp;pmid=22620967&amp;doi=10.3109/13506129.2012.682187&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>
Carr AS, Shah S, Choi D, et al. Spinal stenosis in familial transthyretin amyloidosis. J Neuromuscul Dis
2019;6:267–70. 10.3233/JND-180348
</cite> [<a href="https://doi.org/10.3233/JND-180348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30856118/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neuromuscul%20Dis&amp;title=Spinal%20stenosis%20in%20familial%20transthyretin%20amyloidosis&amp;volume=6&amp;publication_year=2019&amp;pages=267-70&amp;pmid=30856118&amp;doi=10.3233/JND-180348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>
Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol
2017;70:466–77. 10.1016/j.jacc.2017.05.053
</cite> [<a href="https://doi.org/10.1016/j.jacc.2017.05.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28728692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Magnetic%20Resonance%20in%20Transthyretin%C2%A0Cardiac%20Amyloidosis&amp;volume=70&amp;publication_year=2017&amp;pages=466-77&amp;pmid=28728692&amp;doi=10.1016/j.jacc.2017.05.053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>
Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart
2012;98:1442–8. 10.1136/heartjnl-2012-302353
</cite> [<a href="https://doi.org/10.1136/heartjnl-2012-302353" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22865865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart&amp;title=Relative%20apical%20sparing%20of%20longitudinal%20strain%20using%20two-dimensional%20speckle-tracking%20echocardiography%20is%20both%20sensitive%20and%20specific%20for%20the%20diagnosis%20of%20cardiac%20amyloidosis&amp;volume=98&amp;publication_year=2012&amp;pages=1442-8&amp;pmid=22865865&amp;doi=10.1136/heartjnl-2012-302353&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>
Coutinho MCA, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging
2013;6:627–36. 10.1161/CIRCIMAGING.112.000367
</cite> [<a href="https://doi.org/10.1161/CIRCIMAGING.112.000367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23833285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Cardiovasc%20Imaging&amp;title=Reduced%20myocardial%20123-iodine%20metaiodobenzylguanidine%20uptake:%20a%20prognostic%20marker%20in%20familial%20amyloid%20polyneuropathy&amp;volume=6&amp;publication_year=2013&amp;pages=627-36&amp;pmid=23833285&amp;doi=10.1161/CIRCIMAGING.112.000367&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>
Klaassen SHC, Tromp J, Nienhuis HLA, et al. Frequency of and prognostic significance of cardiac involvement at presentation in hereditary Transthyretin-Derived amyloidosis and the value of N-terminal pro-B-type natriuretic peptide. Am J Cardiol
2018;121:107–12. 10.1016/j.amjcard.2017.09.029
</cite> [<a href="https://doi.org/10.1016/j.amjcard.2017.09.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29153245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Frequency%20of%20and%20prognostic%20significance%20of%20cardiac%20involvement%20at%20presentation%20in%20hereditary%20Transthyretin-Derived%20amyloidosis%20and%20the%20value%20of%20N-terminal%20pro-B-type%20natriuretic%20peptide&amp;volume=121&amp;publication_year=2018&amp;pages=107-12&amp;pmid=29153245&amp;doi=10.1016/j.amjcard.2017.09.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>
McColgan P, Viegas S, Gandhi S, et al. Oculoleptomeningeal amyloidosis associated with transthyretin Leu12Pro in an African patient. J Neurol
2015;262:228–34. 10.1007/s00415-014-7594-2
</cite> [<a href="https://doi.org/10.1007/s00415-014-7594-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4289971/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25488473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Oculoleptomeningeal%20amyloidosis%20associated%20with%20transthyretin%20Leu12Pro%20in%20an%20African%20patient&amp;volume=262&amp;publication_year=2015&amp;pages=228-34&amp;pmid=25488473&amp;doi=10.1007/s00415-014-7594-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>
Maia LF, Magalhães R, Freitas J, et al. Cns involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry
2015;86:159–67. 10.1136/jnnp-2014-308107
</cite> [<a href="https://doi.org/10.1136/jnnp-2014-308107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25091367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Cns%20involvement%20in%20V30M%20transthyretin%20amyloidosis:%20clinical,%20neuropathological%20and%20biochemical%20findings&amp;volume=86&amp;publication_year=2015&amp;pages=159-67&amp;pmid=25091367&amp;doi=10.1136/jnnp-2014-308107&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>
Martins da Silva A, Cavaco S, Fernandes J, et al. Age-Dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol
2018;265:299–307. 10.1007/s00415-017-8668-8
</cite> [<a href="https://doi.org/10.1007/s00415-017-8668-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29209781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Age-Dependent%20cognitive%20dysfunction%20in%20untreated%20hereditary%20transthyretin%20amyloidosis&amp;volume=265&amp;publication_year=2018&amp;pages=299-307&amp;pmid=29209781&amp;doi=10.1007/s00415-017-8668-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>
Goyal NA, Mozaffar T. Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: an ALS mimicker. Neurol Genet
2015;1:e18. 10.1212/NXG.0000000000000018
</cite> [<a href="https://doi.org/10.1212/NXG.0000000000000018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4807904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27066555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurol%20Genet&amp;title=Tongue%20atrophy%20and%20fasciculations%20in%20transthyretin%20familial%20amyloid%20neuropathy:%20an%20ALS%20mimicker&amp;volume=1&amp;publication_year=2015&amp;pages=e18&amp;pmid=27066555&amp;doi=10.1212/NXG.0000000000000018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>
Ferraro PM, D’Ambrosio V, Di Paolantonio A, et al. Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci
2021;11:980. 10.3390/brainsci11080980
</cite> [<a href="https://doi.org/10.3390/brainsci11080980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8394946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34439599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Sci&amp;title=Renal%20involvement%20in%20hereditary%20transthyretin%20amyloidosis:%20an%20Italian%20single-centre%20experience&amp;volume=11&amp;publication_year=2021&amp;pages=980&amp;pmid=34439599&amp;doi=10.3390/brainsci11080980&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>
Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol
2012;7:1337–46. 10.2215/CJN.08720811
</cite> [<a href="https://doi.org/10.2215/CJN.08720811" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22537653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20J%20Am%20Soc%20Nephrol&amp;title=Transthyretin%20amyloidosis%20and%20the%20kidney&amp;volume=7&amp;publication_year=2012&amp;pages=1337-46&amp;pmid=22537653&amp;doi=10.2215/CJN.08720811&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>
Reynolds MM, Veverka KK, Gertz MA, et al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol
2017;183:156–62. 10.1016/j.ajo.2017.09.001
</cite> [<a href="https://doi.org/10.1016/j.ajo.2017.09.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28911993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Ophthalmol&amp;title=Ocular%20manifestations%20of%20familial%20transthyretin%20amyloidosis&amp;volume=183&amp;publication_year=2017&amp;pages=156-62&amp;pmid=28911993&amp;doi=10.1016/j.ajo.2017.09.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>
Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res
2019;29:55–63. 10.1007/s10286-019-00628-6
</cite> [<a href="https://doi.org/10.1007/s10286-019-00628-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6763516/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31452022/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Auton%20Res&amp;title=Diagnosis%20and%20treatment%20of%20gastrointestinal%20dysfunction%20in%20hereditary%20TTR%20amyloidosis&amp;volume=29&amp;publication_year=2019&amp;pages=55-63&amp;pmid=31452022&amp;doi=10.1007/s10286-019-00628-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>
Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol
2019;73:2872–91. 10.1016/j.jacc.2019.04.003
</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6724183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31171094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20amyloid%20cardiomyopathy:%20JACC%20state-of-the-art%20review&amp;volume=73&amp;publication_year=2019&amp;pages=2872-91&amp;pmid=31171094&amp;doi=10.1016/j.jacc.2019.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R43">
<span class="label">43.</span><cite>
Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation
2019;140:16–26. 10.1161/CIRCULATIONAHA.118.038169
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.038169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31109193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Natural%20history,%20quality%20of%20life,%20and%20outcome%20in%20cardiac%20transthyretin%20amyloidosis&amp;volume=140&amp;publication_year=2019&amp;pages=16-26&amp;pmid=31109193&amp;doi=10.1161/CIRCULATIONAHA.118.038169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R44">
<span class="label">44.</span><cite>
Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis
2010;11:145–57. 10.1097/CND.0b013e3181d05994
</cite> [<a href="https://doi.org/10.1097/CND.0b013e3181d05994" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20215989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Neuromuscul%20Dis&amp;title=The%20neuromuscular%20manifestations%20of%20amyloidosis&amp;volume=11&amp;publication_year=2010&amp;pages=145-57&amp;pmid=20215989&amp;doi=10.1097/CND.0b013e3181d05994&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R45">
<span class="label">45.</span><cite>
Kollmer J, Sahm F, Hegenbart U, et al. Sural nerve injury in familial amyloid polyneuropathy: Mr neurography vs clinicopathologic tools. Neurology
2017;89:475–84. 10.1212/WNL.0000000000004178
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000004178" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28679600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Sural%20nerve%20injury%20in%20familial%20amyloid%20polyneuropathy:%20Mr%20neurography%20vs%20clinicopathologic%20tools&amp;volume=89&amp;publication_year=2017&amp;pages=475-84&amp;pmid=28679600&amp;doi=10.1212/WNL.0000000000004178&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R46">
<span class="label">46.</span><cite>
Salvalaggio A, Coraci D, Cacciavillani M, et al. Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. J Neurol
2021;268:189–98. 10.1007/s00415-020-10127-8
</cite> [<a href="https://doi.org/10.1007/s00415-020-10127-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7815618/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32749600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Nerve%20ultrasound%20in%20hereditary%20transthyretin%20amyloidosis:%20red%20flags%20and%20possible%20progression%20biomarkers&amp;volume=268&amp;publication_year=2021&amp;pages=189-98&amp;pmid=32749600&amp;doi=10.1007/s00415-020-10127-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R47">
<span class="label">47.</span><cite>
Shouman K, Broski SM, Muchtar E, et al. Novel imaging techniques using <sup>18</sup> F-florbetapir PET/MRI can guide fascicular nerve biopsy in amyloid multiple mononeuropathy. Muscle Nerve
2021;63:104–8. 10.1002/mus.27100
</cite> [<a href="https://doi.org/10.1002/mus.27100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33094511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Novel%20imaging%20techniques%20using%2018%20F-florbetapir%20PET/MRI%20can%20guide%20fascicular%20nerve%20biopsy%20in%20amyloid%20multiple%20mononeuropathy&amp;volume=63&amp;publication_year=2021&amp;pages=104-8&amp;pmid=33094511&amp;doi=10.1002/mus.27100&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R48">
<span class="label">48.</span><cite>
Zeidman LA. Advances in the management of small fiber neuropathy. Neurol Clin
2021;39:113–31. 10.1016/j.ncl.2020.09.006
</cite> [<a href="https://doi.org/10.1016/j.ncl.2020.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33223078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurol%20Clin&amp;title=Advances%20in%20the%20management%20of%20small%20fiber%20neuropathy&amp;volume=39&amp;publication_year=2021&amp;pages=113-31&amp;pmid=33223078&amp;doi=10.1016/j.ncl.2020.09.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R49">
<span class="label">49.</span><cite>
Rousseau A, Cauquil C, Dupas B, et al. Potential role of in vivo confocal microscopy for imaging corneal nerves in transthyretin familial amyloid polyneuropathy. JAMA Ophthalmol
2016;134:983–9. 10.1001/jamaophthalmol.2016.1889
</cite> [<a href="https://doi.org/10.1001/jamaophthalmol.2016.1889" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27367055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Ophthalmol&amp;title=Potential%20role%20of%20in%20vivo%20confocal%20microscopy%20for%20imaging%20corneal%20nerves%20in%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;volume=134&amp;publication_year=2016&amp;pages=983-9&amp;pmid=27367055&amp;doi=10.1001/jamaophthalmol.2016.1889&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R50">
<span class="label">50.</span><cite>
Rezk T, Gilbertson JA, Mangione PP, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res
2019;5:145–53. 10.1002/cjp2.126
</cite> [<a href="https://doi.org/10.1002/cjp2.126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6648380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30740936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pathol%20Clin%20Res&amp;title=The%20complementary%20role%20of%20histology%20and%20proteomics%20for%20diagnosis%20and%20typing%20of%20systemic%20amyloidosis&amp;volume=5&amp;publication_year=2019&amp;pages=145-53&amp;pmid=30740936&amp;doi=10.1002/cjp2.126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R51">
<span class="label">51.</span><cite>
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation
2016;133:2404–12. 10.1161/CIRCULATIONAHA.116.021612
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.116.021612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27143678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Nonbiopsy%20diagnosis%20of%20cardiac%20transthyretin%20amyloidosis&amp;volume=133&amp;publication_year=2016&amp;pages=2404-12&amp;pmid=27143678&amp;doi=10.1161/CIRCULATIONAHA.116.021612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R52">
<span class="label">52.</span><cite>
Kapoor M, Foiani M, Heslegrave A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst
2019;24:314–9. 10.1111/jns.12350
</cite> [<a href="https://doi.org/10.1111/jns.12350" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31583784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Peripher%20Nerv%20Syst&amp;title=Plasma%20neurofilament%20light%20chain%20concentration%20is%20increased%20and%20correlates%20with%20the%20severity%20of%20neuropathy%20in%20hereditary%20transthyretin%20amyloidosis&amp;volume=24&amp;publication_year=2019&amp;pages=314-9&amp;pmid=31583784&amp;doi=10.1111/jns.12350&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R53">
<span class="label">53.</span><cite>
Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid
2020;27:97–102. 10.1080/13506129.2019.1708716
</cite> [<a href="https://doi.org/10.1080/13506129.2019.1708716" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31906707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Plasma%20neurofilament%20light%20chain:%20an%20early%20biomarker%20for%20hereditary%20ATTR%20amyloid%20polyneuropathy&amp;volume=27&amp;publication_year=2020&amp;pages=97-102&amp;pmid=31906707&amp;doi=10.1080/13506129.2019.1708716&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R54">
<span class="label">54.</span><cite>
Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary Transthyretin-Mediated amyloidosis. Neurology
2021;96:e412–22. 10.1212/WNL.0000000000011090
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000011090" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7884985/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33087494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Neurofilament%20light%20chain%20as%20a%20biomarker%20of%20hereditary%20Transthyretin-Mediated%20amyloidosis&amp;volume=96&amp;publication_year=2021&amp;pages=e412-22&amp;pmid=33087494&amp;doi=10.1212/WNL.0000000000011090&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R55">
<span class="label">55.</span><cite>
Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol
2021;268:2109–22. 10.1007/s00415-019-09688-0
</cite> [<a href="https://doi.org/10.1007/s00415-019-09688-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8179912/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31907599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Expert%20consensus%20recommendations%20to%20improve%20diagnosis%20of%20ATTR%20amyloidosis%20with%20polyneuropathy&amp;volume=268&amp;publication_year=2021&amp;pages=2109-22&amp;pmid=31907599&amp;doi=10.1007/s00415-019-09688-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R56">
<span class="label">56.</span><cite>
Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci
2009;287:178–84. 10.1016/j.jns.2009.07.028
</cite> [<a href="https://doi.org/10.1016/j.jns.2009.07.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19709674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Sci&amp;title=Distinct%20characteristics%20of%20amyloid%20deposits%20in%20early-%20and%20late-onset%20transthyretin%20Val30Met%20familial%20amyloid%20polyneuropathy&amp;volume=287&amp;publication_year=2009&amp;pages=178-84&amp;pmid=19709674&amp;doi=10.1016/j.jns.2009.07.028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R57">
<span class="label">57.</span><cite>
Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant
2007;7:235–42. 10.1111/j.1600-6143.2006.01585.x
</cite> [<a href="https://doi.org/10.1111/j.1600-6143.2006.01585.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17061984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Progressive%20wild-type%20transthyretin%20deposition%20after%20liver%20transplantation%20preferentially%20occurs%20onto%20myocardium%20in%20FAP%20patients&amp;volume=7&amp;publication_year=2007&amp;pages=235-42&amp;pmid=17061984&amp;doi=10.1111/j.1600-6143.2006.01585.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R58">
<span class="label">58.</span><cite>
Hurshman AR, White JT, Powers ET, et al. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry
2004;43:7365–81. 10.1021/bi049621l
</cite> [<a href="https://doi.org/10.1021/bi049621l" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15182180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Transthyretin%20aggregation%20under%20partially%20denaturing%20conditions%20is%20a%20downhill%20polymerization&amp;volume=43&amp;publication_year=2004&amp;pages=7365-81&amp;pmid=15182180&amp;doi=10.1021/bi049621l&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R59">
<span class="label">59.</span><cite>
Mangione PP, Porcari R, Gillmore JD, et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A
2014;111:1539–44. 10.1073/pnas.1317488111
</cite> [<a href="https://doi.org/10.1073/pnas.1317488111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3910611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24474780/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Proteolytic%20cleavage%20of%20Ser52Pro%20variant%20transthyretin%20triggers%20its%20amyloid%20fibrillogenesis&amp;volume=111&amp;publication_year=2014&amp;pages=1539-44&amp;pmid=24474780&amp;doi=10.1073/pnas.1317488111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R60">
<span class="label">60.</span><cite>
Owen MC, Gnutt D, Gao M, et al. Effects of in vivo conditions on amyloid aggregation. Chem Soc Rev
2019;48:3946–96. 10.1039/c8cs00034d
</cite> [<a href="https://doi.org/10.1039/c8cs00034d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31192324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem%20Soc%20Rev&amp;title=Effects%20of%20in%20vivo%20conditions%20on%20amyloid%20aggregation&amp;volume=48&amp;publication_year=2019&amp;pages=3946-96&amp;pmid=31192324&amp;doi=10.1039/c8cs00034d&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R61">
<span class="label">61.</span><cite>
Dobson CM, Knowles TPJ, Vendruscolo M. The amyloid phenomenon and its significance in biology and medicine. Cold Spring Harb Perspect Biol
2020;12. 10.1101/cshperspect.a033878. [Epub ahead of print: 03 02 2020].
</cite> [<a href="https://doi.org/10.1101/cshperspect.a033878" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6996456/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30936117/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cold%20Spring%20Harb%20Perspect%20Biol&amp;title=The%20amyloid%20phenomenon%20and%20its%20significance%20in%20biology%20and%20medicine&amp;volume=12&amp;publication_year=2020&amp;pmid=30936117&amp;doi=10.1101/cshperspect.a033878&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R62">
<span class="label">62.</span><cite>
Koike H, Nishi R, Ikeda S, et al. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study. J Neurol Sci
2018;394:99–106. 10.1016/j.jns.2018.09.011
</cite> [<a href="https://doi.org/10.1016/j.jns.2018.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30243104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Sci&amp;title=The%20morphology%20of%20amyloid%20fibrils%20and%20their%20impact%20on%20tissue%20damage%20in%20hereditary%20transthyretin%20amyloidosis:%20an%20ultrastructural%20study&amp;volume=394&amp;publication_year=2018&amp;pages=99-106&amp;pmid=30243104&amp;doi=10.1016/j.jns.2018.09.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R63">
<span class="label">63.</span><cite>
Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet
1993;341:1113–6. 10.1016/0140-6736(93)93127-m
</cite> [<a href="https://doi.org/10.1016/0140-6736(93)93127-m" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8097803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Clinical%20improvement%20and%20amyloid%20regression%20after%20liver%20transplantation%20in%20hereditary%20transthyretin%20amyloidosis&amp;volume=341&amp;publication_year=1993&amp;pages=1113-6&amp;pmid=8097803&amp;doi=10.1016/0140-6736(93)93127-m&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R64">
<span class="label">64.</span><cite>
Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl
2008;14:563–70. 10.1002/lt.21395
</cite> [<a href="https://doi.org/10.1002/lt.21395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18383093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Marked%20regression%20of%20abdominal%20fat%20amyloid%20in%20patients%20with%20familial%20amyloid%20polyneuropathy%20during%20long-term%20follow-up%20after%20liver%20transplantation&amp;volume=14&amp;publication_year=2008&amp;pages=563-70&amp;pmid=18383093&amp;doi=10.1002/lt.21395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R65">
<span class="label">65.</span><cite>
Wilczek HE, Larsson M, Ericzon B-G, et al. Long-term data from the familial amyloidotic polyneuropathy world transplant registry (FAPWTR). Amyloid
2011;18 Suppl 1:193–5. 10.3109/13506129.2011.574354072
</cite> [<a href="https://doi.org/10.3109/13506129.2011.574354072" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21838484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Long-term%20data%20from%20the%20familial%20amyloidotic%20polyneuropathy%20world%20transplant%20registry%20(FAPWTR)&amp;volume=18%20Suppl%201&amp;publication_year=2011&amp;pages=193-5&amp;pmid=21838484&amp;doi=10.3109/13506129.2011.574354072&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R66">
<span class="label">66.</span><cite>
Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl
2009;15:1229–35. 10.1002/lt.21817
</cite> [<a href="https://doi.org/10.1002/lt.21817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19790145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Liver%20transplantation%20for%20familial%20amyloidotic%20polyneuropathy:%20impact%20on%20Swedish%20patients'%20survival&amp;volume=15&amp;publication_year=2009&amp;pages=1229-35&amp;pmid=19790145&amp;doi=10.1002/lt.21817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R67">
<span class="label">67.</span><cite>
Suhr OB, Larsson M, Ericzon B-G, et al. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry. Transplantation
2016;100:373–81. 10.1097/TP.0000000000001021
</cite> [<a href="https://doi.org/10.1097/TP.0000000000001021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4732012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26656838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&amp;title=Survival%20after%20transplantation%20in%20patients%20with%20mutations%20other%20than%20Val30Met:%20extracts%20from%20the%20FAP%20world%20transplant%20registry&amp;volume=100&amp;publication_year=2016&amp;pages=373-81&amp;pmid=26656838&amp;doi=10.1097/TP.0000000000001021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R68">
<span class="label">68.</span><cite>
Ando Y, Terazaki H, Nakamura M, et al. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation
2004;77:345–9. 10.1097/01.TP.0000111516.60013.E6
</cite> [<a href="https://doi.org/10.1097/01.TP.0000111516.60013.E6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14966406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&amp;title=A%20different%20amyloid%20formation%20mechanism:%20de%20novo%20oculoleptomeningeal%20amyloid%20deposits%20after%20liver%20transplantation&amp;volume=77&amp;publication_year=2004&amp;pages=345-9&amp;pmid=14966406&amp;doi=10.1097/01.TP.0000111516.60013.E6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R69">
<span class="label">69.</span><cite>
Conceição I, Evangelista T, Castro J, et al. Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. Muscle Nerve
2010;42:836–9. 10.1002/mus.21806
</cite> [<a href="https://doi.org/10.1002/mus.21806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20928908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Acquired%20amyloid%20neuropathy%20in%20a%20Portuguese%20patient%20after%20domino%20liver%20transplantation&amp;volume=42&amp;publication_year=2010&amp;pages=836-9&amp;pmid=20928908&amp;doi=10.1002/mus.21806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R70">
<span class="label">70.</span><cite>
Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid
2006;13:236–49. 10.1080/13506120600960882
</cite> [<a href="https://doi.org/10.1080/13506120600960882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17107884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Orally%20administered%20diflunisal%20stabilizes%20transthyretin%20against%20dissociation%20required%20for%20amyloidogenesis&amp;volume=13&amp;publication_year=2006&amp;pages=236-49&amp;pmid=17107884&amp;doi=10.1080/13506120600960882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R71">
<span class="label">71.</span><cite>
Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA
2013;310:2658–67. 10.1001/jama.2013.283815
</cite> [<a href="https://doi.org/10.1001/jama.2013.283815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4139164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24368466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Repurposing%20diflunisal%20for%20familial%20amyloid%20polyneuropathy:%20a%20randomized%20clinical%20trial&amp;volume=310&amp;publication_year=2013&amp;pages=2658-67&amp;pmid=24368466&amp;doi=10.1001/jama.2013.283815&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R72">
<span class="label">72.</span><cite>
Ibrahim M, Saint Croix GR, Lacy S, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev
2021;387. 10.1007/s10741-021-10143-4
</cite> [<a href="https://doi.org/10.1007/s10741-021-10143-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34272629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart%20Fail%20Rev&amp;title=The%20use%20of%20diflunisal%20for%20transthyretin%20cardiac%20amyloidosis:%20a%20review&amp;volume=387&amp;publication_year=2021&amp;pmid=34272629&amp;doi=10.1007/s10741-021-10143-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R73">
<span class="label">73.</span><cite>
Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res
2013;6:1011–20. 10.1007/s12265-013-9512-x
</cite> [<a href="https://doi.org/10.1007/s12265-013-9512-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3838581/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24101373/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Transl%20Res&amp;title=Effects%20of%20tafamidis%20on%20transthyretin%20stabilization%20and%20clinical%20outcomes%20in%20patients%20with%20non-Val30Met%20transthyretin%20amyloidosis&amp;volume=6&amp;publication_year=2013&amp;pages=1011-20&amp;pmid=24101373&amp;doi=10.1007/s12265-013-9512-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R74">
<span class="label">74.</span><cite>
Coelho T, Maia LF, da Silva AM, et al. Long-Term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol
2013;260:2802–14. 10.1007/s00415-013-7051-7
</cite> [<a href="https://doi.org/10.1007/s00415-013-7051-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3825212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23974642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Long-Term%20effects%20of%20tafamidis%20for%20the%20treatment%20of%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;volume=260&amp;publication_year=2013&amp;pages=2802-14&amp;pmid=23974642&amp;doi=10.1007/s00415-013-7051-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R75">
<span class="label">75.</span><cite>
Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study. J Neurol Sci
2016;362:266–71. 10.1016/j.jns.2016.01.046
</cite> [<a href="https://doi.org/10.1016/j.jns.2016.01.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26944161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Sci&amp;title=Effects%20of%20tafamidis%20treatment%20on%20transthyretin%20(TTR)%20stabilization,%20efficacy,%20and%20safety%20in%20Japanese%20patients%20with%20familial%20amyloid%20polyneuropathy%20(TTR-FAP)%20with%20Val30Met%20and%20non-Val30Met:%20a%20phase%20III,%20open-label%20study&amp;volume=362&amp;publication_year=2016&amp;pages=266-71&amp;pmid=26944161&amp;doi=10.1016/j.jns.2016.01.046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R76">
<span class="label">76.</span><cite>
Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid
2016;23:178–83. 10.1080/13506129.2016.1207163
</cite> [<a href="https://doi.org/10.1080/13506129.2016.1207163" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5359776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27494299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Early%20intervention%20with%20tafamidis%20provides%20long-term%20(5.5-year)%20delay%20of%20neurologic%20progression%20in%20transthyretin%20hereditary%20amyloid%20polyneuropathy&amp;volume=23&amp;publication_year=2016&amp;pages=178-83&amp;pmid=27494299&amp;doi=10.1080/13506129.2016.1207163&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R77">
<span class="label">77.</span><cite>
Lozeron P, Théaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol
2013;20:1539–45. 10.1111/ene.12225
</cite> [<a href="https://doi.org/10.1111/ene.12225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23834402/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Neurol&amp;title=Effect%20on%20disability%20and%20safety%20of%20Tafamidis%20in%20late%20onset%20of%20Met30%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;volume=20&amp;publication_year=2013&amp;pages=1539-45&amp;pmid=23834402&amp;doi=10.1111/ene.12225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R78">
<span class="label">78.</span><cite>
Coelho T, Inês M, Conceição I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology
2018;91:e1999–2009. 10.1212/WNL.0000000000006543
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000006543" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30333157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Natural%20history%20and%20survival%20in%20stage%201%20Val30Met%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;volume=91&amp;publication_year=2018&amp;pages=e1999-2009&amp;pmid=30333157&amp;doi=10.1212/WNL.0000000000006543&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R79">
<span class="label">79.</span><cite>
Amass L, Li H, Gundapaneni BK, et al. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis
2018;13:225. 10.1186/s13023-018-0947-7
</cite> [<a href="https://doi.org/10.1186/s13023-018-0947-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6296038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30558645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Orphanet%20J%20Rare%20Dis&amp;title=Influence%20of%20baseline%20neurologic%20severity%20on%20disease%20progression%20and%20the%20associated%20disease-modifying%20effects%20of%20tafamidis%20in%20patients%20with%20transthyretin%20amyloid%20polyneuropathy&amp;volume=13&amp;publication_year=2018&amp;pages=225&amp;pmid=30558645&amp;doi=10.1186/s13023-018-0947-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R80">
<span class="label">80.</span><cite>
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med
2018;379:1007–16. 10.1056/NEJMoa1805689
</cite> [<a href="https://doi.org/10.1056/NEJMoa1805689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30145929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tafamidis%20treatment%20for%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=379&amp;publication_year=2018&amp;pages=1007-16&amp;pmid=30145929&amp;doi=10.1056/NEJMoa1805689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R81">
<span class="label">81.</span><cite>
Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail
2021;23:277–85. 10.1002/ejhf.2027
</cite> [<a href="https://doi.org/10.1002/ejhf.2027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8048553/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33070419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Efficacy%20and%20safety%20of%20tafamidis%20doses%20in%20the%20Tafamidis%20in%20transthyretin%20cardiomyopathy%20clinical%20trial%20(ATTR-ACT)%20and%20long-term%20extension%20study&amp;volume=23&amp;publication_year=2021&amp;pages=277-85&amp;pmid=33070419&amp;doi=10.1002/ejhf.2027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R82">
<span class="label">82.</span><cite>
Fox JC, Hellawell JL, Rao S, et al. First-In-Human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin Pharmacol Drug Dev
2020;9:115–29. 10.1002/cpdd.700
</cite> [<a href="https://doi.org/10.1002/cpdd.700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7003869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31172685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Drug%20Dev&amp;title=First-In-Human%20study%20of%20AG10,%20a%20novel,%20oral,%20specific,%20selective,%20and%20potent%20transthyretin%20stabilizer%20for%20the%20treatment%20of%20transthyretin%20amyloidosis:%20a%20phase%201%20safety,%20tolerability,%20pharmacokinetic,%20and%20pharmacodynamic%20study%20in%20healthy%20adult%20volunteers&amp;volume=9&amp;publication_year=2020&amp;pages=115-29&amp;pmid=31172685&amp;doi=10.1002/cpdd.700&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R83">
<span class="label">83.</span><cite>
Judge DP, Heitner SB, Falk RH, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol
2019;74:285–95. 10.1016/j.jacc.2019.03.012
</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.03.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30885685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20Stabilization%20by%20AG10%20in%20Symptomatic%20Transthyretin%20Amyloid%C2%A0Cardiomyopathy&amp;volume=74&amp;publication_year=2019&amp;pages=285-95&amp;pmid=30885685&amp;doi=10.1016/j.jacc.2019.03.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R84">
<span class="label">84.</span><cite>
Bieschke J, Russ J, Friedrich RP, et al. Egcg remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A
2010;107:7710–5. 10.1073/pnas.0910723107
</cite> [<a href="https://doi.org/10.1073/pnas.0910723107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2867908/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20385841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Egcg%20remodels%20mature%20alpha-synuclein%20and%20amyloid-beta%20fibrils%20and%20reduces%20cellular%20toxicity&amp;volume=107&amp;publication_year=2010&amp;pages=7710-5&amp;pmid=20385841&amp;doi=10.1073/pnas.0910723107&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R85">
<span class="label">85.</span><cite>
aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther
2015;9:6319–25. 10.2147/DDDT.S96893
</cite> [<a href="https://doi.org/10.2147/DDDT.S96893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4675646/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26673202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Des%20Devel%20Ther&amp;title=Green%20tea%20extract%20as%20a%20treatment%20for%20patients%20with%20wild-type%20transthyretin%20amyloidosis:%20an%20observational%20study&amp;volume=9&amp;publication_year=2015&amp;pages=6319-25&amp;pmid=26673202&amp;doi=10.2147/DDDT.S96893&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R86">
<span class="label">86.</span><cite>
Sousa L, Coelho T, Taipa R. Cns involvement in hereditary transthyretin amyloidosis. Neurology
2021;97:1111–9. 10.1212/WNL.0000000000012965
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000012965" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34663645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Cns%20involvement%20in%20hereditary%20transthyretin%20amyloidosis&amp;volume=97&amp;publication_year=2021&amp;pages=1111-9&amp;pmid=34663645&amp;doi=10.1212/WNL.0000000000012965&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R87">
<span class="label">87.</span><cite>
Cardoso I, Merlini G, Saraiva MJ. 4'-Iodo-4'-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. Faseb J
2003;17:803–9. 10.1096/fj.02-0764com
</cite> [<a href="https://doi.org/10.1096/fj.02-0764com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12724338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Faseb%20J&amp;title=4'-Iodo-4'-Deoxydoxorubicin%20and%20tetracyclines%20disrupt%20transthyretin%20amyloid%20fibrils%20in%20vitro%20producing%20noncytotoxic%20species:%20screening%20for%20TTR%20fibril%20disrupters&amp;volume=17&amp;publication_year=2003&amp;pages=803-9&amp;pmid=12724338&amp;doi=10.1096/fj.02-0764com&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R88">
<span class="label">88.</span><cite>
Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med
2010;8:74. 10.1186/1479-5876-8-74
</cite> [<a href="https://doi.org/10.1186/1479-5876-8-74" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2922089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20673327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Transl%20Med&amp;title=Synergy%20of%20combined%20doxycycline/TUDCA%20treatment%20in%20lowering%20transthyretin%20deposition%20and%20associated%20biomarkers:%20studies%20in%20FAP%20mouse%20models&amp;volume=8&amp;publication_year=2010&amp;pages=74&amp;pmid=20673327&amp;doi=10.1186/1479-5876-8-74&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R89">
<span class="label">89.</span><cite>
Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid
2012;19 Suppl 1:34–6. 10.3109/13506129.2012.678508
</cite> [<a href="https://doi.org/10.3109/13506129.2012.678508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22551192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Doxycycline%20plus%20tauroursodeoxycholic%20acid%20for%20transthyretin%20amyloidosis:%20a%20phase%20II%20study&amp;volume=19%20Suppl%201&amp;publication_year=2012&amp;pages=34-6&amp;pmid=22551192&amp;doi=10.3109/13506129.2012.678508&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R90">
<span class="label">90.</span><cite>
Benbrahim M, Norman K, Sanchorawala V, et al. A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis. J Cardiovasc Pharmacol
2021;77:544–8. 10.1097/FJC.0000000000001004
</cite> [<a href="https://doi.org/10.1097/FJC.0000000000001004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33657048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Pharmacol&amp;title=A%20review%20of%20novel%20agents%20and%20clinical%20considerations%20in%20patients%20with%20ATTR%20cardiac%20amyloidosis&amp;volume=77&amp;publication_year=2021&amp;pages=544-8&amp;pmid=33657048&amp;doi=10.1097/FJC.0000000000001004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R91">
<span class="label">91.</span><cite>
Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med
2015;373:1106–14. 10.1056/NEJMoa1504942
</cite> [<a href="https://doi.org/10.1056/NEJMoa1504942" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26176329/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Therapeutic%20clearance%20of%20amyloid%20by%20antibodies%20to%20serum%20amyloid%20P%20component&amp;volume=373&amp;publication_year=2015&amp;pages=1106-14&amp;pmid=26176329&amp;doi=10.1056/NEJMoa1504942&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R92">
<span class="label">92.</span><cite>
Ino H, Doi Y, Liefaard L, et al. Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous dose of Miridesap in healthy Japanese subjects. Clin Pharmacol Drug Dev
2019;8:612–8. 10.1002/cpdd.631
</cite> [<a href="https://doi.org/10.1002/cpdd.631" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30556959/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Drug%20Dev&amp;title=Evaluation%20of%20the%20safety,%20tolerability,%20pharmacokinetics,%20and%20pharmacodynamics%20of%20a%20single%20intravenous%20dose%20of%20Miridesap%20in%20healthy%20Japanese%20subjects&amp;volume=8&amp;publication_year=2019&amp;pages=612-8&amp;pmid=30556959&amp;doi=10.1002/cpdd.631&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R93">
<span class="label">93.</span><cite>
Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve
2006;33:609–18. 10.1002/mus.20503
</cite> [<a href="https://doi.org/10.1002/mus.20503" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16421881/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Targeted%20suppression%20of%20an%20amyloidogenic%20transthyretin%20with%20antisense%20oligonucleotides&amp;volume=33&amp;publication_year=2006&amp;pages=609-18&amp;pmid=16421881&amp;doi=10.1002/mus.20503&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R94">
<span class="label">94.</span><cite>
Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid
2012;19 Suppl 1:43–4. 10.3109/13506129.2012.673140
</cite> [<a href="https://doi.org/10.3109/13506129.2012.673140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22494066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Clinical%20development%20of%20an%20antisense%20therapy%20for%20the%20treatment%20of%20transthyretin-associated%20polyneuropathy&amp;volume=19%20Suppl%201&amp;publication_year=2012&amp;pages=43-4&amp;pmid=22494066&amp;doi=10.3109/13506129.2012.673140&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R95">
<span class="label">95.</span><cite>
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med
2018;379:22–31. 10.1056/NEJMoa1716793
</cite> [<a href="https://doi.org/10.1056/NEJMoa1716793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inotersen%20treatment%20for%20patients%20with%20hereditary%20transthyretin%20amyloidosis&amp;volume=379&amp;publication_year=2018&amp;pages=22-31&amp;pmid=29972757&amp;doi=10.1056/NEJMoa1716793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R96">
<span class="label">96.</span><cite>
Coelho T, Yarlas A, Waddington-Cruz M, et al. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol
2020;267:1070–9. 10.1007/s00415-019-09671-9
</cite> [<a href="https://doi.org/10.1007/s00415-019-09671-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7109169/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31853709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Inotersen%20preserves%20or%20improves%20quality%20of%20life%20in%20hereditary%20transthyretin%20amyloidosis&amp;volume=267&amp;publication_year=2020&amp;pages=1070-9&amp;pmid=31853709&amp;doi=10.1007/s00415-019-09671-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R97">
<span class="label">97.</span><cite>
Brannagan TH, Wang AK, Coelho T, et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol
2020;27:1374–81. 10.1111/ene.14285
</cite> [<a href="https://doi.org/10.1111/ene.14285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7496583/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32343462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Neurol&amp;title=Early%20data%20on%20long-term%20efficacy%20and%20safety%20of%20inotersen%20in%20patients%20with%20hereditary%20transthyretin%20amyloidosis:%20a%202-year%20update%20from%20the%20open-label%20extension%20of%20the%20NEURO-TTR%20trial&amp;volume=27&amp;publication_year=2020&amp;pages=1374-81&amp;pmid=32343462&amp;doi=10.1111/ene.14285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R98">
<span class="label">98.</span><cite>
Dyck PJB, Coelho T, Waddington Cruz M, et al. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve
2020;62:509–15. 10.1002/mus.27023
</cite> [<a href="https://doi.org/10.1002/mus.27023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7540369/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32654156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Neuropathy%20symptom%20and%20change:%20Inotersen%20treatment%20of%20hereditary%20transthyretin%20amyloidosis&amp;volume=62&amp;publication_year=2020&amp;pages=509-15&amp;pmid=32654156&amp;doi=10.1002/mus.27023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R99">
<span class="label">99.</span><cite>
Dyck PJB, Kincaid JC, Wiesman JF, et al. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis. Muscle Nerve
2020;62:502–8. 10.1002/mus.27022
</cite> [<a href="https://doi.org/10.1002/mus.27022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7540053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32654212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=mNIS+7%20and%20lower%20limb%20function%20in%20inotersen%20treatment%20of%20hereditary%20transthyretin-mediated%20amyloidosis&amp;volume=62&amp;publication_year=2020&amp;pages=502-8&amp;pmid=32654212&amp;doi=10.1002/mus.27022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R100">
<span class="label">100.</span><cite>
Benson MD, Dasgupta NR, Rissing SM, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid
2017;24:219–25. 10.1080/13506129.2017.1374946
</cite> [<a href="https://doi.org/10.1080/13506129.2017.1374946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28906150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Safety%20and%20efficacy%20of%20a%20TTR%20specific%20antisense%20oligonucleotide%20in%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=24&amp;publication_year=2017&amp;pages=219-25&amp;pmid=28906150&amp;doi=10.1080/13506129.2017.1374946&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R101">
<span class="label">101.</span><cite>
Viney NJ, Guo S, Tai L-J, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail
2021;8:652–61. 10.1002/ehf2.13154
</cite> [<a href="https://doi.org/10.1002/ehf2.13154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7835591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33283485/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESC%20Heart%20Fail&amp;title=Ligand%20conjugated%20antisense%20oligonucleotide%20for%20the%20treatment%20of%20transthyretin%20amyloidosis:%20preclinical%20and%20phase%201%20data&amp;volume=8&amp;publication_year=2021&amp;pages=652-61&amp;pmid=33283485&amp;doi=10.1002/ehf2.13154&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R102">
<span class="label">102.</span><cite>
Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med
2013;369:819–29. 10.1056/NEJMoa1208760
</cite> [<a href="https://doi.org/10.1056/NEJMoa1208760" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23984729/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Safety%20and%20efficacy%20of%20RNAi%20therapy%20for%20transthyretin%20amyloidosis&amp;volume=369&amp;publication_year=2013&amp;pages=819-29&amp;pmid=23984729&amp;doi=10.1056/NEJMoa1208760&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R103">
<span class="label">103.</span><cite>
Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med
2018;379:11–21. 10.1056/NEJMoa1716153
</cite> [<a href="https://doi.org/10.1056/NEJMoa1716153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Patisiran,%20an%20RNAi%20therapeutic,%20for%20hereditary%20transthyretin%20amyloidosis&amp;volume=379&amp;publication_year=2018&amp;pages=11-21&amp;pmid=29972753&amp;doi=10.1056/NEJMoa1716153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R104">
<span class="label">104.</span><cite>
Adams D, Polydefkis M, González-Duarte A, et al. Long-Term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol
2021;20:49–59. 10.1016/S1474-4422(20)30368-9
</cite> [<a href="https://doi.org/10.1016/S1474-4422(20)30368-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33212063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Long-Term%20safety%20and%20efficacy%20of%20patisiran%20for%20hereditary%20transthyretin-mediated%20amyloidosis%20with%20polyneuropathy:%2012-month%20results%20of%20an%20open-label%20extension%20study&amp;volume=20&amp;publication_year=2021&amp;pages=49-59&amp;pmid=33212063&amp;doi=10.1016/S1474-4422(20)30368-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R105">
<span class="label">105.</span><cite>
Obici L, Berk JL, González-Duarte A, et al. Quality of life outcomes in Apollo, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid
2020;27:153–62. 10.1080/13506129.2020.1730790
</cite> [<a href="https://doi.org/10.1080/13506129.2020.1730790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32131641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Quality%20of%20life%20outcomes%20in%20Apollo,%20the%20phase%203%20trial%20of%20the%20RNAi%20therapeutic%20patisiran%20in%20patients%20with%20hereditary%20transthyretin-mediated%20amyloidosis&amp;volume=27&amp;publication_year=2020&amp;pages=153-62&amp;pmid=32131641&amp;doi=10.1080/13506129.2020.1730790&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R106">
<span class="label">106.</span><cite>
Habtemariam BA, Karsten V, Attarwala H, et al. Single-Dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, Vutrisiran, in healthy subjects. Clin Pharmacol Ther
2021;109:372–82. 10.1002/cpt.1974
</cite> [<a href="https://doi.org/10.1002/cpt.1974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32599652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Single-Dose%20pharmacokinetics%20and%20pharmacodynamics%20of%20transthyretin%20targeting%20N-acetylgalactosamine-Small%20interfering%20ribonucleic%20acid%20conjugate,%20Vutrisiran,%20in%20healthy%20subjects&amp;volume=109&amp;publication_year=2021&amp;pages=372-82&amp;pmid=32599652&amp;doi=10.1002/cpt.1974&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R107">
<span class="label">107.</span><cite>
Finn JD, Smith AR, Patel MC, et al. A Single Administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep
2018;22:2227–35. 10.1016/j.celrep.2018.02.014
</cite> [<a href="https://doi.org/10.1016/j.celrep.2018.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29490262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=A%20Single%20Administration%20of%20CRISPR/Cas9%20lipid%20nanoparticles%20achieves%20robust%20and%20persistent%20in%20vivo%20genome%20editing&amp;volume=22&amp;publication_year=2018&amp;pages=2227-35&amp;pmid=29490262&amp;doi=10.1016/j.celrep.2018.02.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R108">
<span class="label">108.</span><cite>
Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol
2019;14:1084–7. 10.1038/s41565-019-0591-y
</cite> [<a href="https://doi.org/10.1038/s41565-019-0591-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31802031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Nanotechnol&amp;title=The%20Onpattro%20story%20and%20the%20clinical%20translation%20of%20nanomedicines%20containing%20nucleic%20acid-based%20drugs&amp;volume=14&amp;publication_year=2019&amp;pages=1084-7&amp;pmid=31802031&amp;doi=10.1038/s41565-019-0591-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R109">
<span class="label">109.</span><cite>
Gillmore JD, Gane E, Taubel J, et al. Crispr-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med
2021;385:493–502. 10.1056/NEJMoa2107454
</cite> [<a href="https://doi.org/10.1056/NEJMoa2107454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34215024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Crispr-Cas9%20in%20vivo%20gene%20editing%20for%20transthyretin%20amyloidosis&amp;volume=385&amp;publication_year=2021&amp;pages=493-502&amp;pmid=34215024&amp;doi=10.1056/NEJMoa2107454&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R110">
<span class="label">110.</span><cite>
Bonaïti B, Olsson M, Hellman U, et al. Ttr familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?
Eur J Hum Genet
2010;18:948–52. 10.1038/ejhg.2010.36
</cite> [<a href="https://doi.org/10.1038/ejhg.2010.36" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2987385/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20234390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Hum%20Genet&amp;title=Ttr%20familial%20amyloid%20polyneuropathy:%20does%20a%20mitochondrial%20polymorphism%20entirely%20explain%20the%20parent-of-origin%20difference%20in%20penetrance?&amp;volume=18&amp;publication_year=2010&amp;pages=948-52&amp;pmid=20234390&amp;doi=10.1038/ejhg.2010.36&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R111">
<span class="label">111.</span><cite>
Castaño A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev
2015;20:163–78. 10.1007/s10741-014-9462-7
</cite> [<a href="https://doi.org/10.1007/s10741-014-9462-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4361302/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25408161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart%20Fail%20Rev&amp;title=Natural%20history%20and%20therapy%20of%20TTR-cardiac%20amyloidosis:%20emerging%20disease-modifying%20therapies%20from%20organ%20transplantation%20to%20stabilizer%20and%20silencer%20drugs&amp;volume=20&amp;publication_year=2015&amp;pages=163-78&amp;pmid=25408161&amp;doi=10.1007/s10741-014-9462-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary data</span></div>
<p>
<a href="/articles/instance/9148983/bin/jnnp-2021-327909supp001.pdf" class="usa-link">jnnp-2021-327909supp001.pdf</a><sup> (138.8KB, pdf) </sup>
</p></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of <strong>BMJ Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1136/jnnp-2021-327909"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/jnnp-2021-327909.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/9148983/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/9148983/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9148983%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9148983/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC9148983/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC9148983/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/35256455/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC9148983/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/35256455/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC9148983/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/9148983/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="j2WOpdtZ7pQ2O2IB6KFkXH8aj8AxFzNBkLJvSYRb4L5y8v1WkYK0LlAK4WQ7i9uf">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
